Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1)Xx_NEWLINE_xXCohort 1 (NSCLC cohort) \r\n* In regards to administration of prior anti-PD-1 or anti PD-L1 antibodies, a patients:\r\n** Must not have experienced a toxicity that led to permanent discontinuation of prior immunotherapy\r\n** All adverse events (AEs) while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study\r\n** Must not have experienced a >= grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: subjects with endocrine AE of =< grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic\r\n** Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE, not have experienced recurrence of an AE if re-challenged, and not currently require maintenance doses of > 10 mg prednisone or equivalent per day\r\n* Eligibility for Food and Drug Administration (FDA)-approved agents targeting the EGFR, ROS1 or ALK pathway, which should be evaluated as per standard of care; exceptions to this requirement may be considered on a case-by-case basis by the principal investigator if the patient was previously treated with another targeted agentXx_NEWLINE_xXUnresolved toxicity (i.e., > grade 1 or above baseline) due to previously administered agents; exception includes: subjects with =< grade 2 neuropathy are eligible for the studyXx_NEWLINE_xXResidual CTCAE ? Grade 2 toxicity from any prior anticancer therapy, with the exception of Grade 2 alopecia or Grade 2 neuropathyXx_NEWLINE_xXPrior sorafenib use > 60 days and/or grade 3 or 4 sorafenib related toxicity; note that prior chemotherapy for HCC or a different cancer is allowableXx_NEWLINE_xXAll adverse events grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopeciaXx_NEWLINE_xXAntibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1Xx_NEWLINE_xXPatients with grade 3 ataxia or grade >1 extrapyramidal movement disorder are not eligibleXx_NEWLINE_xX>= 21 days must have elapsed from infusion of lase dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1Xx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy to grade 1 or baseline; patients with stable, controlled grade 2 adverse events (AEs) such as peripheral neuropathy, hypothyroidism, hypertension, adrenal insufficiency or alopecia are allowed after discussing with the PIXx_NEWLINE_xXAny grade I DCISXx_NEWLINE_xXAny grade II DCIS without comedonecrosisXx_NEWLINE_xXGrade II DCIS with comedonecrosisXx_NEWLINE_xXPrior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy, or radiation must have recovered to grade =< 1 with the exception of alopecia and the criteria outlinedXx_NEWLINE_xXPatients must not have experienced a grade 3 or worse immune-related adverse event (irAE) (except asymptomatic nonbullous/nonexfoliative rash) or any unresolved irAE grade 2, nor have experienced a toxicity that led to permanent discontinuation of prior anti-PD-1/PD-L1 immunotherapyXx_NEWLINE_xXPatients who had prior grade 3 or higher immune-related adverse event (e.g. pneumonitis, hepatitis, colitis, endocrinopathy) with prior immunotherapy (e.g. cancer vaccine, cytokine, etc.) are not eligibleXx_NEWLINE_xXSTEP II: Any adverse event related to step 1 therapy must have resolved to grade 2 or lessXx_NEWLINE_xXPatients must have recovered to =< grade 2 following a significant adverse event or toxicity attributed to previous anti-cancer treatment except neurotoxicity which must be =< grade 1Xx_NEWLINE_xXPrior to randomization patients with any non-hematologic toxicity from surgery, chemotherapy and radiation therapy must have recovered to grade =< 1 with the exception of alopecia, ototoxicity and neuropathyXx_NEWLINE_xXPatients must have recovered from all clinically relevant adverse events to grade 1 or baseline due to previous agents administered (except alopecia)Xx_NEWLINE_xXPatients must have recovered from adverse events (toxicities resolved to grade 1 or less) of prior therapy; patients with immune related toxicities from ipilimumab + nivolumab may continue onto Step 2 even if still on steroids to control side effects, so long as toxicity has resolved to grade 1 or lessXx_NEWLINE_xXPatients with GOG performance grade of 3 or 4Xx_NEWLINE_xXAll adverse events associated with any prior surgery and intravesical therapy must have resolved to grade =< 2 prior to registrationXx_NEWLINE_xXAntibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1Xx_NEWLINE_xXCNS toxicity =< grade 2Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXTreatment-related toxicity from prior therapy > grade 2Xx_NEWLINE_xXPatient has an unresolved ? Grade 2 adverse event (AE) from a previous antineoplastic treatment, excluding alopecia and phlebitisXx_NEWLINE_xXRecovered to ? grade 1 NCI CTCAE version 4.0 from toxicity of prior chemotherapy or biologic therapy administered more than 4 weeks earlier.Xx_NEWLINE_xXPersistent clinically significant toxicities (>= CTCAE version [v.] 4.0 grade 2) caused by previous cancer therapy, with the exception of alopeciaXx_NEWLINE_xXPresence of ? CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior cancer therapyXx_NEWLINE_xXHas had a prior monoclonal antibody, chemotherapy, or targeted small molecule therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier (alopecia is an exception)\r\n* Note: Subjects with =< grade 2 neuropathy or ototoxicity are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXOngoing toxic manifestations of previous treatments. Exceptions to this are alopecia or certain Grade 1 toxicities, which in the opinion of the investigator should not exclude the participant a. Any known history of Grade 4 thrombocytopenia with any prior chemotherapy regimenXx_NEWLINE_xXAny prior >= grade 4 immune-related adverse event while receiving immunotherapy; patients will be excluded if experiencing any unresolved grade 3 immune related adverse events at the time of study entry; participants with a history of hypersensitivity to compounds of similar biologic composition to tremelimumab or any constituent of the productXx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy that have not resolved to CTCAE, version 4.0, grade =< 1 or baseline, with the exception of alopecia and laboratory values listedXx_NEWLINE_xXTreatment with chemotherapy or investigational drugs within 21 days prior to the screening visit. Acute toxicities from prior therapy must have resolved to Grade ? 1 above baseline.Xx_NEWLINE_xXWith the exception of alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists any unresolved toxicities from prior therapy greater than CTCAE grade 1 at time of study treatmentXx_NEWLINE_xXPre-existing Grade 2 or higher chronic diarrhoeaXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > Grade 1 (except hemoglobin value) and/or that is progressing in severity, except alopeciaXx_NEWLINE_xX9. Unresolved toxicities from prior anticancer therapy defined as having not resolved to baseline or to Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia;Xx_NEWLINE_xXThe interval between last nivolumab or pembrolizumab and start of study treatment should be at least 21 days with no residual anti-PD-1-related immune toxicities in excess of Grade 1 severity.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 30 days prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent.Xx_NEWLINE_xXNote: Subjects with ? Grade 2 neuropathy or ? Grade 2 alopecia are an exception to this criterion and may qualify for the study.Xx_NEWLINE_xXOngoing adverse effects from prior systemic treatment > NCI CTCAE Grade 1 (with the exception of Grade 2 alopecia)Xx_NEWLINE_xXHas not recovered from the adverse effect of previous anticancer treatments to pre-treatment baseline or Grade 1 except for alopecia, anemia (hemoglobin must meet the study inclusion criteria) and peripheral neuropathy (which must have recovered to ? Grade 2).Xx_NEWLINE_xXPersisting toxicity related to prior therapy (NCI CTCAE v4.03 Grade > 1)Xx_NEWLINE_xXHas received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study allocation. (Notes: Participants must have recovered from all AEs due to previously administered therapies to ? Grade 1 or baseline. If a participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment.)Xx_NEWLINE_xXParticipants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXResolution of toxicity from prior anti-cancer therapy, to NCI CTCAE v4.03 Grade 0 or 1, except for alopecia. Subjects may be enrolled if their toxicity is determined to be irreversible and will not put them at undue risk from study treatment, based on the Investigator's assessment.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovery to =< grade 1 or baseline of any toxicity due to prior systemic treatments, excluding alopeciaXx_NEWLINE_xXUnresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version 4.0 grade 1 (with the exception of myelosuppression, eg, neutropenia, anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior antitumor therapy that are considered irreversible (defined as having been present and stable for > 2 months) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsor.Xx_NEWLINE_xXOngoing adverse event from previously administered systemic anti-cancer therapy unless has recovered to =< grade 1 or at baseline prior to C1D1\r\n* Subjects with any grade alopecia or =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXAdverse events from prior anti-cancer therapy that have not resolved to Grade ? 1. Clinically stable patients with manageable immune-related adverse events resulting from prior cancer immunotherapy may be eligible for the study.Xx_NEWLINE_xXMust not have experienced any ? Grade 3 AE nor any neurologic or ocular AE of any grade while receiving prior checkpoint inhibitors.Xx_NEWLINE_xXSubject has toxicity from previous anticancer therapy that has not recovered to ? Grade 1 or to their baseline level of organ function prior to enrollment (except for non-clinically significant toxicities, e.g., alopecia, vitiligo).Xx_NEWLINE_xXResidual side effects to previous therapy > grade 1 prior to randomization (Alopecia any grade and/or neuropathy grade 2 without pain are permitted)Xx_NEWLINE_xX>= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1Xx_NEWLINE_xXCNS toxicity =< grade 2Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent;\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documentedXx_NEWLINE_xXSubjects must have recovered from treatment toxicities to =< grade 1 or to their pretreatment levels; subjects who have developed interstitial lung disease (ILD) must have fully recoveredXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Major surgical procedure, or significant traumatic injury within 28 days of registration or incompletely healed surgical wounds are exclusions; minor surgical procedures such as placement of central venous device (excluding peripherally inserted central catheter [PICC] line) are allowed 7 days prior to enrollment to the studyXx_NEWLINE_xXAt least two weeks from last systemic therapy for breast cancer, with recovery of all treatment related toxicity to grade 1 or less; subjects with =< grade 2 neuropathy are an exception to this criterionXx_NEWLINE_xXAt least two weeks from last radiation therapy, with recovery of all treatment related toxicity to grade 1 or less (excluding alopecia)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAt least 2 weeks since the last systemic therapy regimen prior to enrollment. Subjects must have recovered to NCI CTCAE v4.03 Grade 1 or less from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.Xx_NEWLINE_xXGrade >1 gastrointestinal toxicity that cannot be managed with supportive care measures.Xx_NEWLINE_xXUnresolved toxicity from prior chemotherapy (subjects must be recovered to ? Grade 1 toxicity from previous anticancer treatments or previous investigational products.Xx_NEWLINE_xXParticipants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy =< 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously\r\nadministered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPresence of ? CTCAE grade 2 toxicity (except alopecia and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior cancer therapy.Xx_NEWLINE_xXParticipants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatient has had a prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXSubject has recovered (i.e., to Grade ? 1 or to a baseline level) from the effects of surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer; with the exception of vitiligo, alopecia, neuropathy, partial hearing loss, and/or endocrinopathies (for which no resolution is required);Xx_NEWLINE_xXSubject has any Grade ? 2 persistent non-hematological toxicity related to allotransplantXx_NEWLINE_xXAll ACT related toxicities resolved to grade 1 with the exception of alopecia, vitiligo and endocrine abnormalities requiring replacement therapy which may be grade 2Xx_NEWLINE_xXCOHORT 1: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks or growth factors within 1 week prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study.\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXCOHORT 2: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks or growth factors within 1 week prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHistory of CTCAE >= grade 2 immune mediated endocrinopathy from prior cancer immunotherapyXx_NEWLINE_xXPresence of ? CTCAE Grade 2 toxicity due to prior cancer therapy.Xx_NEWLINE_xXAt least 1 week since the last systemic therapy regimen prior to Cycle 1 Day 1. Subjects must have recovered to NCI CTCAE v. 4.03 < Grade 2 from all acute toxicities (excluding Grade 2 toxicities that are not considered a safety risk by the Sponsor and Investigator) or toxicity must be deemed irreversible by the Investigator.Xx_NEWLINE_xXAll clinically significant toxicities from prior systemic therapy must be =< grade 1 (with the exception of alopecia, endocrinopathies associated with prior immunological therapies as long as they are stable with replacement therapy, and peripheral neuropathy, which may be =< grade 2)Xx_NEWLINE_xXSAFETY RUN-IN: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXRANDOMIZED PHASE II CLINICAL TRIAL: Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXUnresolved chronic toxicity > grade 1 from prior therapyXx_NEWLINE_xXAll associated clinically significant toxicity from previous cancer therapy must be resolved (to ?Grade 1 or baseline) prior to study treatment administration (Grade 2 alopecia is allowed).Xx_NEWLINE_xXGrade ?2 ventricular arrhythmia ?6 months prior to Day 1Xx_NEWLINE_xXParticipants must have recovered to grade =< 1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include but are not limited to alopecia, laboratory values listed per inclusion criteria and lymphopenia)Xx_NEWLINE_xXMajor surgery or treatment with any chemotherapy, radiation therapy, biologics for cancer or investigational therapy in the 28 days before the first dose of study treatment (subjects with prior cytotoxic or investigational products <3 weeks prior to study treatment might be eligible after discussion between the Investigator and Medical Monitor, if toxicities from the prior treatment have been resolved to NCI CTCAE Grade 1). All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 or baseline before the first dose of study treatment. Subjects with toxicities attributed to prior anti-cancer therapy which are not expected to resolve and result in long lasting sequelae, such as neuropathy after platinum based therapy, are permitted to enrolXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to cycle 1 day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXConcurrent administration of any other anti-cancer therapy\r\n* Bisphosphonates and denosumab for bone metastases are allowed as long as these were started at least 4 weeks prior to treatment with study drug\r\n* Octreotide is allowed if dose is stable for > 3 months with no worsening of carcinoid syndrome\r\n* Hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for medical castration in patients with castrate-resistant prostate cancer is permitted\r\n* Most recent chemotherapy within 3 weeks prior to entering the study\r\n* Therapeutic radiotherapy within the previous 3 weeks if =< 5% of their total marrow volume or 4 weeks if > 5% of their total marrow volume, or unresolved acute or subacute toxicities from prior radiotherapy\r\n* Most recent experimental (non-FDA approved) anti-cancer therapy or immunotherapies =< 30 days or five half-lives of the drug (whichever is less)\r\n* Patients who have not recovered to =< Common Terminology Criteria for Adverse Events (CTCAE) grade 1 toxicities related to prior therapy (administered more than 3 weeks earlier) or incomplete recovery from previous surgery, unless agreed by the principal investigator (PI) and documented are not eligible to participate in this study with the exception of grade 2 peripheral neuropathy if it has been stable, and not worsening, for at least 28 days, and grade 2 alopeciaXx_NEWLINE_xXPersistent toxicities (>= CTCAE grade 2) with the exception of alopecia, caused by previous cancer therapyXx_NEWLINE_xXFailed to recover from the reversible effects of prior anticancer therapies with the exception of alopecia and grade 2 neuropathyXx_NEWLINE_xXAntibodies: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1Xx_NEWLINE_xXActive residual toxicity from prior therapies.Xx_NEWLINE_xXRecovery to =< grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopeciaXx_NEWLINE_xXParticipants must have fully recovered (grade =< 1 or baseline or deemed irreversible) from any clinically significant acute toxicity related to prior therapy (with the exception of lymphopenia, which is common after therapy with temozolomide); patients who discontinued bevacizumab previously due to a bevacizumab-related toxicity will not be allowed to participateXx_NEWLINE_xXPatients in whom prior treatment related toxicities have not recovered to grade 1 or less (except for alopecia)Xx_NEWLINE_xXHas an EGFR TKI- related toxicity that has NOT resolved to Grade 1 or less.Xx_NEWLINE_xXHas not recovered from reversible toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, or Grade 1 neuropathy)Xx_NEWLINE_xXRecovery to Grade 1 or baseline of any toxicity due to prior systemic treatments or radiotherapy (excluding alopecia).Xx_NEWLINE_xXGrade 2 or greater toxicities due to previous therapies, subject to laboratory abnormalities listed below. Stable, tolerable Grade 2 adverse events may be allowed at discretion of InvestigatorXx_NEWLINE_xXNot recovered to less than or equal to Grade 1 toxicities (except Grade 2 alopecia or neuropathy) associated with previous cancer therapiesXx_NEWLINE_xXHas unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v4, grade =< 1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the Investigator and Sponsor (eg, grade 2 chemotherapy-induced neuropathy).Xx_NEWLINE_xXParticipant has not adequately recovered from toxicity of previous therapyXx_NEWLINE_xXA life-threatening (Grade 4) immune-mediated adverse event related to prior immunotherapy.Xx_NEWLINE_xXFailure to recover from any immune-related toxicity from prior cancer therapy to ? Grade 1.Xx_NEWLINE_xXFailure to recover from any other toxicity (other than immune-related toxicity) related to previous anticancer treatment to ? Grade 2.Xx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy resolved to Grade ?1 before baseline, with the exception of alopecia and neurotoxicity (CTCAE Grade 1 or 2 permitted).Xx_NEWLINE_xXPatients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia).Xx_NEWLINE_xXParticipants must not have experienced a grade >= 3 immune-related adverse event (AE) or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy, or experienced a toxicity of any grade that led to permanent discontinuation of prior immunotherapy as a result of the toxicity. Participants with prior endocrine adverse events of grade =< 2 are permitted to enroll if stably maintained on appropriate replacement therapy and are asymptomatic. In the setting of prior immune-related AE, participants must not have required the use of additional immunosuppressive agents other than corticosteroids for the management of the adverse event(s), not have experienced recurrence of the adverse event if re-challenged, and not currently requiring maintenance doses of > 10 mg of prednisone or equivalent per day at the time of enrollment.Xx_NEWLINE_xXThe subjects who have not recovered to baseline or CTCAE ? Grade 1 from related toxicity to all prior therapies will be excluded. Patients with Non-serious adverse events such as alopecia, fatigue, weakness, loss of appetite and nausea that are non-significant will not be excluded.Xx_NEWLINE_xXParticipants who have not recovered to =< CTCAE grade 1 or baseline from toxicity as a result of previous cancer treatment prior to entering the study (with the exception of alopecia and peripheral neuropathy which can be =< grade 2)Xx_NEWLINE_xXChemotherapy, radiotherapy, and/or biological cancer therapy within 3 weeks prior to the first trial dose or has not recovered to CTCAE v.4 grade 1 or better from adverse events (except alopecia).Xx_NEWLINE_xXChemotherapy, targeted small molecule therapy, radiation therapy, hormonal treatment or immunotherapy within 21 days prior to initiation of treatment. A 6-week washout period will be required for those with prior PD-1 or PD-L1 treatment. Subjects must have resolution of toxic effect(s) of the most recent therapy to Grade 1 or less. Exceptions are subjects with ? Grade 2 alopecia or ? Grade 2 neuropathy who are permitted in the study. If the subject received major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or any complications from the intervention.Xx_NEWLINE_xXHas resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the participant received major surgery or radiation therapy of >30 Gray units, they must have recovered from the toxicity and/or complications from the interventionXx_NEWLINE_xXCTCAE Version 4, Grade 4 non-hematological toxicity (except for alopecia, nausea, vomiting).Xx_NEWLINE_xXAcute toxicities from any prior anti-tumor therapy, surgery, or radiotherapy that has not resolved to Grade </=2, except alopeciaXx_NEWLINE_xXReceipt of the last dose or treatment of anti-cancer chemotherapy, radiotherapy, surgery, endocrine therapy, targeted therapy, biologic therapy, or tumor embolization =< 2 weeks (4 weeks for any monoclonal antibody (mAb), 6 weeks for nitrosoureas or mitomycin C) prior to first dose of study treatment, or has not recovered (i.e., to =< grade 1 or Baseline) from clinically significant adverse events (AEs) due to these previously administered agents\r\n* Note: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with other irreversible toxicity (e.g., hearing loss) or reversible toxicity (e.g. alopecia) that is not reasonably expected to be exacerbated by the investigational product and is not expected to interfere with study participation may be included\r\n* Note: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatient must have recovered to Grade 1 toxicity from prior cancer therapyXx_NEWLINE_xXSubjects must have resolution of toxic effect(s) from prior therapy to Grade 1 or less. Subjects with ? Grade 2 neuropathy or alopecia are an exception to this criterion. If a subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention to Grade 1 or lessXx_NEWLINE_xXParticipants must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the studyXx_NEWLINE_xXPatients must have recovered from adverse events (greater than grade 1) due to prior anticancer therapy, except for stable chronic toxicities such as alopeciaXx_NEWLINE_xXAny prior >= grade 3 immune-related adverse event (irAE) while receiving immunotherapy, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.Xx_NEWLINE_xXAcute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03.Xx_NEWLINE_xXAny adverse events related to previous therapies for breast cancer that have not resolved to ?Grade 1.Xx_NEWLINE_xXToxicities due to prior therapy must be stable and recovered to =< grade 1 (except for clinically non-significant toxicities, such as alopecia, nutritional support measures, electrolyte abnormalities, or those not impacting the investigator’s ability to assess treatment emergent toxicities)Xx_NEWLINE_xXPatients are not eligible who have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to registration or who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXGrade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapyXx_NEWLINE_xXGrade >= 2 toxicity (other than alopecia) continuing from prior anti-cancer therapyXx_NEWLINE_xXAny anti-cancer treatment (except for radiation therapy) within 21 days, or any investigational agent within 30 days prior to the first dose of study drug; participants should have recovered from any toxicity related to previous anti-cancer treatment to Common Toxicity Criteria (CTC) grade 0 or 1.Xx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Patients must have recovered to =< grade 1 in terms of toxicity from prior treatments (excluding neuropathy which can be =< grade 2, and alopecia)Xx_NEWLINE_xXAll toxicities (except alopecia) from prior cancer treatments must have resolved to ? Grade 1 or returned to baseline levels prior to enrollmentXx_NEWLINE_xXCohorts 1, 2, and 3: Patients with low-grade ovarian cancer (eg, low grade serous, mucinous carcinoma) are not eligibleXx_NEWLINE_xXPatients may have received prior radiation, chemoembolization, radioembolization or other local ablative therapies or hepatic resection if completed >= 4 weeks prior to registration AND if patient has recovered to =< grade 1 toxicityXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to registration, or who has not recovered (i.e., =< grade 1 or baseline) from adverse events (AEs) due to previously administered agentsXx_NEWLINE_xXMust not have experienced a Grade ?3 immune-related AE or an immune-related neurologic or ocular AE, pneumonitis or cardiomyopathy of any grade while receiving prior immunotherapy.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy other than pre-specified allowed agents, or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubjects with known persistent (> 4 weeks) >= grade 2 toxicity from prior cancer therapyXx_NEWLINE_xXSubjects with known >= grade 3 hematological toxicity with the last chemotherapy regimenXx_NEWLINE_xXAny history of a prior >= grade 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade 2 neuropathy or chemotherapy-induced alopecia are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXPrior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer: systemic or IT) must have been completed at least 4 weeks prior to enrollment and all adverse events have either returned to baseline (or resolved to < grade 1); note: subjects who have received prior platinum therapy are eligible irrespective of their response.Xx_NEWLINE_xXThere are no limits on prior lines of therapy; however, patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia)Xx_NEWLINE_xXPatients with grade > 1 neuropathy or grade > 1 toxicity (except alopecia or anorexia) from prior therapyXx_NEWLINE_xXWashout of at least 3 weeks from prior chemotherapy or targeted therapy that induces myelosuppression and recovery of treatment related adverse events to grade 1 or less, with the exception of alopecia, is required prior to the start of palbociclibXx_NEWLINE_xXReceived prior chemotherapy, an immune checkpoint inhibitor, or radiation therapy within 2 weeks prior to study registration or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events from previously administered agents. NOTE: Subjects with alopecia, grade ? 2 sensory neuropathy or other grade ? 2 AEs not constituting a safety risk based on investigator judgement are an exception to this criterion and can still be considered for the study.Xx_NEWLINE_xX> = 21 days must have elapsed from infusion of last dose of antibody and toxicity related to prior antibody therapy must have recovered to Grade <= 1.Xx_NEWLINE_xXPresence of any of the following conditions, which are risk factors for RVO: Uncontrolled glaucoma with intraocular pressure >21 millimetres of mercury (mm Hg); Serum cholesterol >/=Grade 2; Hypertriglyceridemia >/=Grade 2; Hyperglycemia (fasting) >/=Grade 2; Grade >/=2 uncontrolled hypertension (participants with a history of hypertension controlled with anti-hypertensive medication to Grade </=1 are eligible)Xx_NEWLINE_xXAll acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1 prior to study entryXx_NEWLINE_xXPatients who are newly OR previously diagnosed with low grade glioma (LGG), who have not been treated with any modality besides surgery or corticosteroids; untreated astrocytomas or other eligible tumors (with the exception of subependymal giant cell astrocytoma) interpreted as low grade (World Health Organization [WHO] grade I and II), will be eligible for the study as below (4th edition WHO classification of central nervous system [CNS] tumors); if it is clinically suspected that the previously untreated progressive low grade astrocytoma has evolved to a higher grade tumor, it is recommended a biopsy be performed; patients with metastatic disease are allowed on studyXx_NEWLINE_xXUncontrolled chronic diarrhea > grade 2 at baseline.Xx_NEWLINE_xXGrade > 1 toxicity from prior therapy (except alopecia or anorexia)Xx_NEWLINE_xXPatients must have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia)Xx_NEWLINE_xXGrade 3 or higher toxicity effects from previous treatment with immunotherapyXx_NEWLINE_xXParticipants who have not recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to the study.Xx_NEWLINE_xXHistologically proven diagnosis of high-grade glioma, including anaplastic glioma (WHO grade III with 1p/19q chromosomes intact), glioblastoma (WHO grade IV) or gliosarcoma (WHO Grade IV);Xx_NEWLINE_xXUnresolved toxicity higher than CTCAE (v. 4.03) Grade 1 attributed to any prior therapy/procedure excluding alopecia and hypothyroidism;Xx_NEWLINE_xXHave not recovered from toxicity of prior therapy defined as a return to < grade 1 at the time of dose assignment, graded according to CTCAE v4.03 (excluding alopecia, neuropathy, and lymphopenia)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXUnresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure excluding alopeciaXx_NEWLINE_xXHistory of grade 4 immune-related adverse events requiring treatment with prednisone, or grade 3 immune-related adverse events requiring prednisone > 10 mg/kg for > 12 weeks, if previously treated with ipilimumabXx_NEWLINE_xXPatient has not recovered (i.e., =< grade 1 or baseline) from adverse events due to prior anti-cancer therapy;\r\n* Note: patients with =< grade 2 neuropathy are eligibleXx_NEWLINE_xXPatient has had a prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment.Xx_NEWLINE_xXPatients with history of any grade 4 toxicity during previous anti PD-1 treatment or history of grade 3 or higher pneumonitisXx_NEWLINE_xXHave had any prior Grade ?3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, have any unresolved irAE Grade >1, or any irAE that led to the permanent discontinuation of prior immunotherapy.Xx_NEWLINE_xXHave experienced a Grade ?3 AE or a neurologic or ocular AE of any grade while receiving prior immunotherapy.Xx_NEWLINE_xXExperienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade <1 (except alopecia or neuropathy).Xx_NEWLINE_xXHas received treatment with chemotherapy, targeted small molecule therapy, or radiation therapy to non-liver sites within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent administered more than 2 weeks earlier\r\n* Subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study\r\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHistologically confirmed low grade (grade 1 or grade 2) noninvasive (Ta) urothelial carcinoma of the bladder with a new recurrence that meets the following criteria:\r\n* Total tumor burden =< 3 cm in size (multiple lesions permitted)\r\n* Low grade appearance (grade 1 or grade 2)\r\n* Noninvasive appearance (Ta)\r\n* No history of carcinoma in situ (CIS) within the last 3 years or lesions concerning for CIS\r\n* Negative urine cytology (atypical or suspicious for low grade neoplasm are considered negative) within 5 years\r\n* Eligible for surgery\r\n* Urothelial carcinoma of the bladder recurrence can be confirmed by either cystoscopic visual evaluation or histologic evaluation of a biopsy sampleXx_NEWLINE_xXHistory of high grade diseaseXx_NEWLINE_xXThe patient has persistent clinically significant ?Grade 2 toxicities from previous anticancer therapy (excluding Grade 2 chemotherapy-related neuropathy which is permitted, and excluding Grade 2-3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the Investigator, and can be managed with available medical therapies).Xx_NEWLINE_xXHas had prior chemotherapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 2 or at baseline) from adverse events due to a previously administered agent and meeting the criteria for organ function; patients who receive palliative radiation therapy within 1 week prior to day 1 are allowed; patients on treatment with targeted therapy (like EGFR or ALK TKIs) may start study treatment 5 days from last treatment; NOTE: subjects with =< grade 2 neuropathy or other clinically insignificant adverse events (AEs) as determined by the PI are an exception to this criterion and may qualify for the study following adequate pre-study documentation; NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXRecovery to grade ? 1 or to baseline from any adverse event (AE) derived from previous treatment (excluding alopecia and/or cutaneous toxicity and/or peripheral neuropathy and/or fatigue grade ? 2).Xx_NEWLINE_xXUnresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version 4.0 grade 1Xx_NEWLINE_xXUnresolved CTCAE >Grade 2 toxicity (other than stable toxicity) from previous anti-cancer therapy excluding alopecia.Xx_NEWLINE_xXDehydration ? grade 1Xx_NEWLINE_xXToxicity from prior therapy (except alopecia) has resolved to ?Grade 1; in the event of toxicity that has not resolved to ?Grade 1 but is considered stable, the patient may be eligible after discussion among the investigator and sponsor's medical monitor.Xx_NEWLINE_xXHave any unresolved chronic toxicity with CTC AE grade >= 2, from previous anti-NF1 therapy, except for alopeciaXx_NEWLINE_xXPatients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade ?1 (CTCAE v 4.03). Patients with grade ? 2 peripheral neuropathy or any grade of alopecia, fatigue, nail changes or skin changes are allowed to enter the studyXx_NEWLINE_xXPatients may have received prior chemotherapy, crizotinib (other ALK inhibitors are not allowed), biologic therapy or other investigational agents. Patients must have recovered from all toxicities related to prior anticancer therapies to grade ? 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.Xx_NEWLINE_xXToxicity related to any prior therapy must either have returned to =< grade 1 or baselineXx_NEWLINE_xXLOW GRADE B-NHL PATIENTS ONLYXx_NEWLINE_xXPrior chemotherapy or radiation therapy =< 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMust have fully recovered from toxicities of any prior treatment with cytotoxic drugs, radiotherapy, surgery, or other anti-cancer modalities (returned to baseline status as noted before most recent treatment or =< grade 1)Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of MK-3475 or has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXNote: patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if a patient underwent major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baselineXx_NEWLINE_xXAny prior grade >= 3 immune related adverse events immune-mediated adverse events (imAE) while receiving immunotherapy, including anti-cytotoxic T-lymphocyte protein 4 (CTLA4) treatment, or any unresolved imAE > grade 1; Note: active or history of vitiligo will not be a basis for exclusionXx_NEWLINE_xXPatients must have recovered all toxicities from prior therapy or radiation to grade 1 or less (excluding alopecia)Xx_NEWLINE_xXHave not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous IPs.Xx_NEWLINE_xXAt least 3 weeks beyond the last chemotherapy, targeted anticancer agent, major surgery or experimental treatment and recovered from all acute toxicities (? Grade 1). Hydroxyurea used to control peripheral blast counts is permitted up to Day 7 of treatment on study.Xx_NEWLINE_xXMore than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding at the time the patient receives the preparative regimen, and patient’s toxicities must have recovered to a grade 1 or lessXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); patients must have progressive disease after prior treatment; note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXPatient has recovered (to Grade ?1) from all clinically significant toxicities related to prior antineoplastic therapies (with the exception of alopecia)Xx_NEWLINE_xXPatients must be either intolerant or refractory to one or more standard line(s) of chemotherapy treatment prior to enrollment; toxicity from prior regimens must be resolved to less than or equal to grade 1 prior to enrollment; patients with grade 2 neurotoxicity may be enrolled on a case by case basis at the discretion of the principal investigator; patients should be off all treatment for at least 4 weeks prior to trial enrollmentXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)\r\n* Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less; patients may have undergone minor surgical procedures with the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specifiedXx_NEWLINE_xXOngoing prior toxicities related to previous treatments must be recovered to < grade 2 at the time of registration (with the exception of alopecia, grade 2 peripheral neuropathy or lymphopenia)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., =< Grade 1 or at baseline) from adverse events due to a previously administered agent.\r\n* Note: Subjects with =< Grade 2 neuropathy are an exception to this criterion and may qualify for the study.\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.Xx_NEWLINE_xXSymptomatic loco-regional disease that causes ongoing grade 3 or grade 4 urinary or rectal symptomsXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual drug related toxicities > grade 1) except for alopecia and grade 2 fatigueXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to grade 1 or less (except for toxicities such as alopecia or vitiligo).\r\n* Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less.Xx_NEWLINE_xXRecovery from recent surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ? Grade 1 (other than alopecia); ? Grade 2 neuropathy allowedXx_NEWLINE_xXAny prior grade ? 3 immune-related adverse event (irAE) while receiving a prior immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXGrade >= 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiationXx_NEWLINE_xXPrior treatment-related toxicity resolved to =< grade 2 or baselineXx_NEWLINE_xXPatients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapyXx_NEWLINE_xXResidual side effects to previous therapy > Grade 1 prior to initiation of therapy (Alopecia any grade and/or neuropathy Grade 1 without pain are permitted)Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the immunization regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)Xx_NEWLINE_xXToxicities related to prior therapy must have returned to Grade 1 or less, except for alopecia.Xx_NEWLINE_xXPatient with any active immune toxicity of Grade 1 or greater or any other severe or Grade 3 treatment-related adverse event.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n*Note: subjects with =< grade 2 neuropathy due to chemotherapy are an exception to this criterion and may qualify for the study\r\n*Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas not recovered from prior surgery, chemotherapy or radiation therapy from adverse events due to a previous treatment/ administered agent (i.e., ? grade 1 or return to baseline prior to treatment)\r\n* Note: Subjects with ? grade 2 neuropathy, any grade hearing loss or tinnitus, or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documentedXx_NEWLINE_xXInadequate recovery from adverse events related to prior therapy to grade ? 1 (excluding grade 2 alopecia and neuropathy)Xx_NEWLINE_xXAcute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade </=1 prior to study entryXx_NEWLINE_xXAt least 4 weeks after any prior chemoembolization, radioembolization, local ablative therapies, or hepatic radiation and recovery to =< grade 1 treatment-related toxicityXx_NEWLINE_xXAt least 7 days after minor surgery (such as central venous access) or biopsy and recovery to =< grade 1 treatment-related toxicityXx_NEWLINE_xXAt least 2 weeks after any prior palliative radiation (e.g. to focal metastatic lesion such as bone metastases) and recovery to =< grade 1 treatment-related toxicityXx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment, with the exception of alopecia or neuropathyXx_NEWLINE_xXParticipants must not have had prior chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for disease-specific hormone treatments considered standard of care) within 2 weeks prior to study day 1 or have not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXOngoing severe graft-versus-house disease (GVHD) with Grade ?2 serum bilirubin, Grade ?3 skin involvement, or Grade ?3 diarrhea at the start of study therapy.Xx_NEWLINE_xXHistory of any of the following toxicities associated with a prior immunotherapy: \r\n* Grade > 3 immune mediated adverse event that was considered related to previous immunotherapy and required immune suppressive therapy\r\n* Immune mediated adverse event that was considered related to previous immunotherapy and is still > grade 1 with immune suppressive therapyXx_NEWLINE_xXFailure to recover to grade 1 or baseline from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, immunotherapy, and/or experimental therapy, with the exception of: alopecia, grade =< 2 peripheral neuropathy, grade =< 2 cetuximab-related rash or other skin changes, hypomagnesemia (acceptable values detailed below), hypokalemia (acceptable values detailed below), and the acceptable hematologic values summarized above; a washout period of 2 weeks from prior cetuximab is required; a washout period of 3 weeks from any prior cytotoxic chemotherapy, targeted therapy, immunotherapy or investigational drug is requiredXx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy resolved to ?Grade 1 before the start of study therapy (with the exception of alopecia [Grade 1 or 2 permitted], or neurotoxicity [Grade 1 or 2 permitted], or selected laboratory parameters [Grade 1 or Grade 2 permitted with exceptions as noted below]).Xx_NEWLINE_xXNeuropathy as residual toxicity after prior antitumor therapy Grade >2Xx_NEWLINE_xXAll adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved to grade 1 or baseline, except for alopecia and sensory neuropathy Grade ? 2, or other Grade ? 2 not constituting a safety risk based on investigator's judgment, are acceptable.Xx_NEWLINE_xXHas had a prior chemotherapy, immunotherapy, biological therapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy, alopecia or hypothyroidism are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy events due to a previously administered agentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, a minimum of four weeks must have passed and they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less; patients may have undergone minor surgical procedures within the past three weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXFor cohort 3, more than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding at the time the patient receives the preparative regimen, and patient’s toxicities must have recovered to a grade 1 or lessXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study at the discretion of the treating provider\r\n* Note: If subject received major surgery, they must have recovered adequately, in the opinion of the treating provider, from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubject has not recovered from adverse reactions to prior cancer treatment or procedures (surgery, chemotherapy, immunotherapy, radiation therapy) to CTCAE Grade 2 or better.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent.\r\n* Note: Subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion.\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention as determined by the investigators prior to starting therapy.Xx_NEWLINE_xXGENERAL: Adverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia.Xx_NEWLINE_xXSubjects who have received any prior cytotoxic therapy, immunotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks or 5 half-lives, whichever is shorter, prior to course 1, day 1 (C1D1) (6 weeks prior for checkpoint inhibitors such as anti-CTLA-4 or anti-PD1/PD-L1 and for nitrosoureas or mitomycin C); subjects must not have received radiotherapy in the 2 weeks prior to C1D1; subjects who had grade >= 3 immune-related adverse event (irAE) during previous treatment with one of the checkpoint inhibitors are excluded from the trial; subjects who had grade 1 or 2 irAE that have resolved to grade 1 are eligibleXx_NEWLINE_xXRecovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administrationXx_NEWLINE_xXPersisting toxicity related to prior therapy >Grade 1Xx_NEWLINE_xXAll anticancer- and radiation therapy-related toxicities must be completely resolved or downgraded to Grade 1 or less (neuropathy may be Grade 2 or less).Xx_NEWLINE_xXResolution of all chemotherapy or radiation-related toxicities to ? Grade 1Xx_NEWLINE_xXResolution of all clinically significant treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to =< grade 1 prior to the first dose of study treatmentXx_NEWLINE_xXSystemic anti-cancer treatment within 2 weeks, and all ongoing adverse events resolved to grade ? 1Xx_NEWLINE_xXIn immunotherapy pretreated patients, any history of dose-limiting toxicity with prior immunotherapy agents, including grade 3/4 immune-related adverse events (irAEs); irreversible irAEs; grade >= 3 irAEs that did not respond to steroid rescue; or neurologic irAE with significant clinical sequelaeXx_NEWLINE_xXAny toxicity (> CTCAE version 4 grade 3) from previous anti-cancer therapy that has not resolved to a grade 1; persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy; patients with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy, alopecia)Xx_NEWLINE_xX> 21 days from therapeutic radiation or chemotherapy (>6 weeks from nitrosoureas and mitomycin C) and recovery to (NCI CTCAE v4.03) Grade ? 1 from all clinically significant toxicities related to prior therapies.Xx_NEWLINE_xXRecovery to baseline or =< grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless adverse events (AEs) are clinically nonsignificant and/or stable on supportive therapy.Xx_NEWLINE_xXThe subject has not recovered to baseline or CTCAE =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant AEs.Xx_NEWLINE_xXPatients who experienced grade 3 or above skin toxicity from prior EGFR inhibiting therapyXx_NEWLINE_xXPatients who have experienced grade 3 or above toxicity from prior anti-PD1 therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXResidual or ongoing ? Grade 3 toxicity from chemotherapyXx_NEWLINE_xXAdverse events from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 28 days prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study with principal investigator (PI) approval\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Cycle1/ Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent(s). Note: Patients with ? Grade 2 neuropathy are an exception to this criterion and may qualify for the trial. Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Subjects with =< grade 2 hematologic toxicities are an exception to this criterion and may qualify for the study\r\n* Note: Subjects with =< grade 2 fatigue are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPrior chemotherapy, targeted therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered (i.e. to =< grade 1 or baseline) from an adverse event due to the previously administered therapyXx_NEWLINE_xXPatients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPrior chemotherapy or targeted small molecule therapy of the current sarcoma. In patients with locally recurrent disease, previous systemic chemotherapy of the primary tumor is allowed, as long as treatment was completed prior to study enrollment and patient has recovered (i.e., < grade 1 or at baseline) from any adverse events due to previously administered agents.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the vaccine, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)\r\n* Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) except alopecia are ineligibleXx_NEWLINE_xXAll associated clinically significant drug-related toxicity from previous cancer therapy must be resolved prior to study treatment administration (alopecia is allowed).Xx_NEWLINE_xXPersistent, unresolved ?Grade 2 clinically significant drug-related toxicity (except alopecia, erectile impotence, hot flashes, libido, neuropathy) associated with previous treatmentXx_NEWLINE_xXUnresolved toxicities from prior antitumor therapy, defined as not having resolved to CTCAE, version 4.0 grade 1 (with the exception of myelosuppression, e.g., neutropenia, anemia, thrombocytopenia), or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior antitumor therapy that are considered irreversible (defined as having been present and stable for > 2 months) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and sponsorXx_NEWLINE_xXAll adverse events grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved to grade 1 or baseline, except for alopecia and sensory neuropathy grade =< 2, or other grade =< 2 not constituting a safety risk based on investigator’s judgment, are acceptableXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. - Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. - Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.Xx_NEWLINE_xXToxicity related to prior treatments must either have resolved to grade 1 or less, returned to baseline, or be deemed irreversibleXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parametersXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXHas a diagnosis of active GvHD (>= grade I); patients with prior active GvHD that is quiescent (grade 0) at time of entry may be consideredXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.Xx_NEWLINE_xXPatients must have received no more than 3 prior therapies for recurrent high grade glioma (rHGG)Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, radiation, hormonal, monoclonal antibody (mAb) or targeted small molecule therapy, within 2 weeks prior to the first study procedure (apheresis); subjects who have not recovered to < grade 3 from an adverse event due to a previously administered agent are not eligibleXx_NEWLINE_xXHas been receiving erlotinib, gefitinib, or afatinib for at least 6 weeks with well-controlled related toxicities less than Grade 3 in severity at the time of screening period.Xx_NEWLINE_xXPre-existing and ongoing radiation-related grade 3 bowel or bladder toxicityXx_NEWLINE_xXResidual side effects to previous therapy > grade 1 prior to initiation of therapy (alopecia any grade and/or neuropathy grade 2 without pain are permitted)Xx_NEWLINE_xX>= grade 3 thromboembolic event in the last 6 monthsXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHave resolution of all previous treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (less than or equal to Grade 2) or alopecia. If subject received major surgery or radiation therapy of > 30 Gy, must have recovered from the toxicity and/or complications from the intervention.Xx_NEWLINE_xXHad a prior anti-cancer monoclonal antibody (other than pembrolizumab) within 30 days prior to start of study treatment, or failure to recover to CTCAE Grade 1 or better from the adverse events of prior therapiesXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXMust have recovered (i.e., adverse event [AE] =< grade 1 or stable) from AEs due to a previously administered agentXx_NEWLINE_xXRadiation therapy =< 2 weeks prior to study entry; patients who have received prior radiotherapy must have recovered from toxicity (=< grade 1) induced by this treatment (except for alopecia)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery or radiation, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: anti-estrogen therapy must be stopped prior to study day 1Xx_NEWLINE_xXToxicities due to prior therapy must be stable and recovered to =< grade 1 (except for clinically non significant toxicities such as alopecia)Xx_NEWLINE_xXAll prior treatment-related toxicities must be CTCAE (version 4.03) =< grade 1 (except alopecia) at the time of randomizationXx_NEWLINE_xXHad prior chemotherapy, targeted small molecule therapy within 4 weeks, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent \r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: patients who have received > 30 Gy to the thorax must have completed this radiation 6 months prior to enrollment in the studyXx_NEWLINE_xXGrade 3 or 4 non-hematological, treatment-related adverse event (AE)sXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny unresolved toxicity (> CTCAE version [v]4 grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripheral neuropathy)Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to registration or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXLast dose of prior therapy must be > 21 days before the first dose of study drug administration; there is no upper limit to number of prior therapies; however, the patient must have recovered from acute toxicities from the most recent therapy to grade 1 or lessXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n** Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients must have recovered from treatment toxicities to =< grade 1 or to their pretreatment levels except for adverse events (AEs) that in the investigator’s judgment do not constitute a safety risk for the patientXx_NEWLINE_xXHistory of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, central serous chorioretinopathy, retinal vein occlusion (RVO), or neovascular macular degeneration; patients will be excluded from study participation if they are currently known to have any of the following risk factors for RVO:\r\n* Glaucoma with intraocular pressure >= 21 mmHg\r\n* Grade >= 2 serum cholesterol (patients with a history of elevated cholesterol controlled with lipid lowering medication to grade =< 1 are eligible)\r\n* Grade >= 2 hypertriglyceridemia (patients with a history of elevated cholesterol controlled with lipid lowering medication to grade =< 1 are eligible)\r\n* Grade >= 2 or symptomatic hyperglycemia (fasting); hyperglycemia may be corrected with medications to grade =< 1\r\n* Grade >= 2 uncontrolled hypertension (patients with a history of hypertension controlled with anti-hypertensive medication to grade =< 1 are eligible)Xx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia and neuropathyXx_NEWLINE_xXGrade 3 or above neuropathy induced from prior treatment, that is not resolved to grade 2 or below despite best supportive careXx_NEWLINE_xXPatients will be excluded if they currently have the following risk factors for retinal vein occlusion (RVO): (1) uncontrolled glaucoma with intra-ocular pressures >= 21 mmHg (2) serum cholesterol >= grade 2 (3) hypertriglyceridemia >= grade 2 (4) hyperglycemia (fasting) >= grade 2Xx_NEWLINE_xXhave inadequate recovery* from adverse events resulting from previously-administered anti-cancer therapies; [*Note: Unless more specifically defined in Inclusion Criteria 6, 7 and 8 above, adequate recovery is defined as improvement to ? Grade 2 for any other hematologic toxicity and for peripheral neuropathy, and improvement to ? Grade 1 for any other non-hematologic toxicity.]Xx_NEWLINE_xXPatient has not recovered from toxicity from prior immune checkpoint inhibitor therapy. Recovery is defined as ? NCI-CTCAE Grade 1, except for liver function test levels which must be <Grade 1.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or to baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: if subject received major surgery, they must have recovered adequately from surgery prior to starting therapyXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients receiving hormone manipulation (e.g. tamoxifen, aromatase inhibitors, LHRH agonist, etc.) for reasons other than treatment of metastatic breast cancer may continue this treatment at the discretion of the investigatorXx_NEWLINE_xXExisting severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade 3 except for hearing loss, alopecia, anorexia, nausea, and hypomagnesemia from total parenteral nutrition (TPN), which may be grade 3Xx_NEWLINE_xXHave resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the patient received major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from AEs due to a previously administered agent.Xx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopeciaXx_NEWLINE_xX(Bevacizumab-related exclusion) Any previous venous thromboembolism > NCI CTCAE grade 3Xx_NEWLINE_xXAny unresolved toxicity (>= CTCAE grade 2) from previous anti-cancer therapy, excluding alopeciaXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with =< grade 2 hypertension managed with medication are an exception to this criterion and may qualify for the study\r\n* Note: subjects with =< grade 2 endocrinopathy (e.g. hypothyroidism or adrenal insufficiency managed with medication) are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXPrior treatment with immune checkpoint inhibitors is allowed, provided that no treatment-related grade >= 3 adverse events (other than grade 3 endocrinopathy managed with replacement therapy) were observed and at least a minimum of 28 days have elapsed between the last dose of prior treatment and the proposed cycle 1 day 1Xx_NEWLINE_xXParticipants treated with prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to the prior chemotherapy, targeted small molecule therapy, and radiation therapy\r\n* Note: Subjects with =< grade 2 neuropathy and/or alopecia are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have had the surgery > 2 weeks prior to study day 1 and recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXParticipants with any prior >= grade 3 immune-related adverse event (irAE) which began while receiving immunotherapyXx_NEWLINE_xXParticipants with any unresolved immune-related adverse event (irAE) at time of study entry\r\n* Note: Subjects with =< grade 2 thyroiditis and/or hypophysitis are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXAny unresolved >= grade 2 pulmonary toxicity from previous anti-cancer therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPatients who have not recovered to =< grade 1 or tolerable grade 2 from adverse events due to agents administered >= 28 days earlier are not eligibleXx_NEWLINE_xXAny unresolved grade 2 or higher toxicity from previous anti-cancer therapyXx_NEWLINE_xXRecovered from any toxicity to grade 2 or less from all prior chemotherapy, immunotherapy or radiotherapy and be at least 30 days past the date of their last treatment with the exception of mitotane which may be continuedXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1); Note: Patients with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study; Note: If patients received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXChemotherapy, monoclonal antibody, targeted small molecule therapy, within 4 weeks prior to dose #1 or who has not recovered (i.e., =< grade 1 or at baseline) for adverse events due to a previously administered agent (excluding alopecia or toxicity not anticipated to interfere with planned treatment on study)Xx_NEWLINE_xXRecovered from any prior treatment related toxicity to at least Grade 1 with exception of Grade 2 alopecia or other Grade 2 toxicity with prior approval of the Medical MonitorXx_NEWLINE_xXAny prior immune-related adverse event (irAE) >= grade 2 while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baselineXx_NEWLINE_xXPatients will be excluded from study participation if they currently are known to have any of the following risk factors for RVO: a. Glaucoma with intraocular pressure >= 21 mmHg b. Grade >= 2 serum cholesterol c. Grade >= 2 hypertriglyceridemia d. Grade >= 2 or symptomatic hyperglycemia (fasting) e. Grade >= 2 uncontrolled hypertension (patients with a history of hypertension controlled with anti-hypertensive medication to grade =< 1 are eligibleXx_NEWLINE_xX(For both cohorts A and B): Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia)Xx_NEWLINE_xXParticipants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., =< grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXNo more than grade 2 toxicity with last previous cycle of regorafenib mono therapyXx_NEWLINE_xXPatients must have recovered from toxicity related to prior therapy to at least grade 1 (defined by CTCAE 4.0) or baseline level. Chronic stable grade 2 peripheral neuropathy secondary to neurotoxicity from prior therapies may be considered on a case by case basis by the Principal Investigator.Xx_NEWLINE_xXPatients with history of any Grade 3 or Grade 4 adverse events from prior ipilimumab therapy, if administered in the past.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovery (i.e., to grade 1 or baseline) from all clinically significant adverse event (AE)s related to prior therapies (excluding alopecia, neuropathy, and nail changes)Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE grade =< 1 with the exception of alopecia and laboratory values listed per the inclusion criteria. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (eg, hearing loss)Xx_NEWLINE_xXHistory of grade 3 or higher immune-mediated adverse event (including AST/ALT elevations that where considered drug related and cytokine release syndrome) that was considered related to prior immune-modulatory therapy (e.g., checkpoint inhibitors, costimulatory agents etc.) or any grade immune-related adverse events (AEs) that required immune suppressive therapyXx_NEWLINE_xXUnresolved grade 2 or greater toxicity from most recent treatment, including chemotherapy, hormonal therapy, or radiotherapy, at the time of study enrollmentXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPatient has had a prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPatient has had prior grade 4 infusion reaction to cetuximabXx_NEWLINE_xXHas had prior targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubjects with history of grade 3 toxicity or use of infliximab with prior immunotherapyXx_NEWLINE_xXPrior chemotherapy, radiotherapy, biological cancer therapy, targeted small molecule therapy or major surgery within 21 days prior to study day 1 or who has not recovered (i.e., to CTCAE =< grade 1 or at baseline) from adverse events due to previously administered therapy, Note: subjects with =< grade 2 neuropathy and alopecia are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAll non-hematological toxicity of previous cancer therapy should have resolved to =< grade 1 (except alopecia or other toxicities not involving major organs)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion\r\nand may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXOnly for subjects enrolled in Arm 2 - Neratinib and palbociclib: any prior neuropathy should be back to baseline or grade 1.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiotherapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPresence of grade 3 or greater toxicity from the previous treatment.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXResolution of all treatment-related, non-hematological toxicities, except alopecia, from any previous cancer therapy to < grade 1 prior to the first dose of study treatmentXx_NEWLINE_xXPatients who have residual toxicities > grade 2 attributed to taxane therapy, except for neuropathy, who are excluded if > grade 1Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of study drug or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXPresence of unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 grade 0 or 1 with the exception of alopecia; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by regorafenib (e.g. hearing loss, neuropathy) may be included after consultation with the principal investigatorXx_NEWLINE_xXPrior treatment-related toxicities that have not resolved to ? Grade 1 before the date of study drug administration except for stable chronic toxicities (? Grade 2) not expected to resolve (eg, stable Grade 2 peripheral neurotoxicity).Xx_NEWLINE_xXPrior chemotherapy or radiation therapy =< 2 weeks prior to registration or who has not recovered (i.e. to =< grade 1 or baseline) from an adverse event due to the previously administered therapyXx_NEWLINE_xXExisting major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade 3, with the exception of hearing loss and hematologic toxicityXx_NEWLINE_xXRecovered from reversible toxicities of prior therapy to grade 0 or grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1.Xx_NEWLINE_xXAdverse events (AEs) from prior anti-cancer therapy that have not resolved to grade =< 1 except for alopecia and neuropathyXx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopeciaXx_NEWLINE_xXUnresolved toxicity higher than NCI-CTCAE version 4.03 grade 1 attributed to any prior therapy/procedure excluding anemia or neuropathy grade 2 and alopecia of any gradeXx_NEWLINE_xXResolved acute effects of any prior AML/MDS therapy to baseline or ? Grade 1 CTCAE severity.Xx_NEWLINE_xXMust have recovered (i.e., =< grade 1 or at baseline) from adverse events of any previous treatment; note: surgical resection for recurrent tumor prior to enrollment is allowedXx_NEWLINE_xXAt least 2 weeks beyond prior treatment (chemotherapy, investigational drugs including small molecular inhibitors, endocrine therapy, immunotherapy and/or radiation therapy) or major surgery, and recovered from all acute toxicities to Grade 1 or less (except alopecia and peripheral neuropathy).Xx_NEWLINE_xXOtherwise, all toxicity at study entry < Grade 1 by NCI CTCAE v4.00 (Patients with ? Grade 2 neuropathy are eligible).Xx_NEWLINE_xXResolution of all toxicities from prior therapy to ?Grade 1 (or baseline) within 1 week prior to the first dose of study drug (excluding alopecia and ?Grade 3 clinically asymptomatic lipase, amylase, and creatine phosphokinase laboratory abnormalities).Xx_NEWLINE_xXPatient must have completed prior chemotherapy at least 2 weeks (washout period) prior to randomization and recovered from toxicity to Grade 1 or baselineXx_NEWLINE_xXAll side effects attributed to prior anti-cancer therapy must have resolved to Grade 1 or baselineXx_NEWLINE_xXGrade >= 3 non-hematologic toxicity from prior therapy that has not resolved to =< grade (G) 1Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients must be 4 weeks out from major proceduresXx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade ? 1 except for alopeciaXx_NEWLINE_xXHistory of grade 4 immune-related adverse events requiring treatment with prednisone or history of grade 3 immune-related adverse events requiring prednisone > 10 mg/kg for > 12 weeksXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy who has not recovered (i.e., =< grade 1 or at baseline level) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXInadequate recovery from adverse events related to prior therapy to grade =< 1 (excluding grade 2 alopecia and neuropathy)Xx_NEWLINE_xXAll prior treatment-related toxicities resolved to =< grade 1 or are determined to be clinically stable by the investigatorXx_NEWLINE_xXSubjects with low grade tumors (histologic grade 1/3)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAdverse events from previous cancer therapies (excluding alopecia) must have recovered to grade 1 (CTCAE, most recent version). Stable grade 2 AEs such as endocrine conditions are allowed, and other chronic stable AEs may be considered on a case by case basis by the Principal Investigator.Xx_NEWLINE_xXGrade 2 or higher pneumonitisXx_NEWLINE_xXParticipant has unresolved adverse events greater than grade 1 from prior anticancer therapy except for alopecia.Xx_NEWLINE_xXAt least 4 weeks (wks) since prior radiation or surgery with full recovery (no persistent toxicity >= grade 1)Xx_NEWLINE_xXRecovery to =< grade 1 from all toxicities associated with prior therapy except alopeciaXx_NEWLINE_xXGrade ?2 hypotension at screeningXx_NEWLINE_xXHas had prior chemotherapy, radiation, or targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent;\r\n* Note: Subjects with alopecia or =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Lesions that have been selected for HDCRT may have been previously radiated provided:\r\n** The tumor site that was previously radiated has progressed.\r\n** A baseline biopsy of the tumor site is obtained following progression and prior to study entry\r\n* Note: Subjects currently receiving androgen deprivation therapy or hormonal therapy are allowed\r\n* Note: Subjects receiving nitrosoureas within 6 weeks prior to study day 1 are excludedXx_NEWLINE_xXPatients with active infection, un-resolving more than grade 2 transplant-related toxicitiesXx_NEWLINE_xXHas experienced immune-related adverse events (AEs) (irAEs) while receiving prior immunotherapy (including anti-CTLA4 treatment) and assessed as CTCAE grade >= 3Xx_NEWLINE_xXBaseline toxicities from prior anti-cancer treatments > grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with ? Grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubjects must not have received chemotherapy or targeted small molecule therapy within 4 half-lives of the specific agent(s), or radiation therapy within 2 weeks prior to the first dose of study medication, and must have recovered (=< grade 1) from adverse events related to a previously administered agentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n- Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 and who have not recovered adequately from this treatment (=< grade 2 toxicity at the time of enrollment)Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; patients must be 4 weeks out from major procedures and 2 weeks out from minor proceduresXx_NEWLINE_xXHas received locoregional therapy to liver (transarterial chemoembolization (TACE), transarterial embolization (TAE), radiation, radioembolization, or ablation) or surgery to liver or other site within 6 weeks prior to the first dose of study drug; minor surgery must have occurred at least 7 days prior to the first dose of study treatment (cycle 1, day 1); subjects must have recovered adequately (i.e., grade =< 1 or baseline) from the toxicity and/or complications from any intervention prior to starting therapyXx_NEWLINE_xXFor participants entering cohorts C or D, prior treatment-related toxicities should have resolved to grade 1 or baseline (with the exception of anemia (as per inclusion criteria, alopecia, and neuropathy [=< grade 2 allowed])Xx_NEWLINE_xXPrior radiation or surgery must have completed at least 2 weeks prior to initiation of therapy and all toxicities or complications from these must have resolved to baseline or grade 1 prior to starting therapy (with the exception of anemia (as per inclusion criteria, alopecia, and neuropathy [=< grade 2 allowed])Xx_NEWLINE_xXAny toxicity related to prior treatment must have resolved to Grade 1 or less, with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathyXx_NEWLINE_xXPatients that had grade 3/4 immune-related adverse events (AEs) on ipilimumab that required more than 12 weeks of immune suppression with corticosteroidsXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered small molecule agent; a. Note: subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study; b. Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHave resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia); if subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the interventionXx_NEWLINE_xXResidual or on-going >= grade 3 treatment-related toxicity from previous chemotherapy should be resolvedXx_NEWLINE_xXParticipant has recovered from toxicities of prior chemotherapy or other therapy (to grade 2 or less)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: participants with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy and, has to be at least 28 days after the surgeryXx_NEWLINE_xXAdverse events from prior anticancer therapy that have not resolved to grade =< 1 except for alopeciaXx_NEWLINE_xXHas recovered from all therapy-related toxicity to =< grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy) at the time of registrationXx_NEWLINE_xXHave any unresolved chronic toxicity with CTCAE grade >= 2, from previous anti-NF1 therapy, except for alopeciaXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; prior radiotherapy to the liver is not allowed\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHydroxyurea may be used to control leukocytosis, provided that it is without grade > 2 toxicity, and can be taken until start of therapyXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)\r\n* Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXChemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXOngoing acute treatment-related toxicity associated with a previous therapy greater than grade 1 except for grade 2 alopecia or neuropathy.Xx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baselineXx_NEWLINE_xXPatients who have unresolved toxicity from all radiation, adjuvant/neoadjuvant chemotherapy, other targeted treatment including investigational treatment (exception of alopecia and ? Grade 2 peripheral neuropathy) according to NCI-CTCAE v4.03 criteriaXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent \r\n* Note: subjects with grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients who have had chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day -14 or who have not recovered (to =< grade 1 or baseline) from adverse events due to a previously administered agent are not eligible\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and do qualify for the study\r\n* Note: if subject received major surgery within 4 weeks prior to day -14, they must have recovered adequately from the toxicity and/or complications per principal investigator (PI) discretionXx_NEWLINE_xXMust not have experienced a Grade ?3 immune-related AE or an immune-related neurologic or ocular AE of any grade while receiving prior immunotherapy.Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteriaXx_NEWLINE_xXmCRPC EXPANSION COHORT: The patient has not recovered to baseline or CTCAE =< grade 1 from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy or with hematologic toxicity that has recovered to levels above that stated in inclusion criterion are an exception to this criterion and may qualify for the study if all other inclusion/exclusion criteria are met\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention (i.e., =< grade 1 or at baseline) prior to starting therapyXx_NEWLINE_xXTo be eligible for study treatment, toxicity from prior treatment must recover to Grade ? 1, except for alopeciaXx_NEWLINE_xXTo be eligible for study treatment, radiation therapy-related toxicity must recover to Grade ? 1 prior to administration of the first dose of ARQ 751.Xx_NEWLINE_xXPrior chemotherapy < 2 weeks prior to study drug treatment and treatment related adverse events that have not recovered to baseline or grade 1 (alopecia excluded); prior radiation therapy < 4 weeks prior to study drug treatmentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas received prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current gynecologic malignancy\r\n* Note: subjects who have received treatment for a prior unrelated malignancy must have recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXFailed to recover to baseline or stable grade 1 from the reversible effects of prior anticancer therapies with the exception of alopeciaXx_NEWLINE_xXAny unresolved toxicity (> CTCAE grade 2) from previous anti-cancer therapy; any prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAll acute treatment-related toxicities from prior therapy must have resolved to grade =< 1 prior to study entry excluding alopeciaXx_NEWLINE_xXPatients must have recovered from all treatment-related toxicities to Grade 1 or less.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (ie, =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previous treatment\r\n* Note: subjects with permanent =< grade 2 toxicities (e.g. neuropathy) or toxicities corrected through routine medical management (e.g. thyroid replacement for hypothyroidism) are an exception to this criterion and may qualify for the study\r\n** Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n*** Note: subjects with asymptomatic =< grade 2 laboratory or dermatologic abnormalities are an exception to this criterion and may qualify for the study pending the judgment of the treating radiation oncologistXx_NEWLINE_xXPatients exhibiting baseline grade 3 or 4 by CTCAE criteria are excludedXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovery from adverse events of previous systemic anti-cancer therapies to baseline or grade 1, except for:\r\n* Alopecia\r\n* Stable neuropathy of =< grade 2 due to prior cancer therapyXx_NEWLINE_xXHas no prior treatment-related toxicities >Grade 1 (except alopecia) at the time of enrolment.Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 3 weeks prior to administration of the study drug or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; *Note: Subjects with permanent =< grade 2 toxicities (e.g. neuropathy) or toxicities corrected through routine medical management (e.g. thyroid replacement for hypothyroidism), are an exception to this criterion and may qualify for the study; *Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; *Note: Subjects with =< grade 2 amylase or lipase elevations abnormalities that have no corresponding clinical manifestations (e.g. manifestation of pancreatitis), are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXHas experienced grade 4 toxicity on treatment with prior radiationXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: For grade 4 neutropenia, ? grade 3 febrile neutropenia, or grade 4 thrombocytopenia, hold bendamustine until toxicity resolve to ? grade 2Xx_NEWLINE_xXPatients must have recovered to less than grade 1 or to baseline from toxicity of prior chemotherapy or biologic therapy and must not have had major surgery, chemotherapy, radiation or biologic therapy within 2 weeks prior to beginning treatment; NOTE: Exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study treatment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; previous radiation to extracranial sites may be completed at any time prior to initiation of pembrolizumab;\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parametersXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXHas had prior chemotherapy, or targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients with GOG performance grade of 3 or 4Xx_NEWLINE_xXRecovery from adverse events of previous systemic anti-cancer therapies to baseline or grade 1, except for: \r\n* Alopecia\r\n* Stable neuropathy of =< grade 2 due to prior cancer therapyXx_NEWLINE_xXAny toxicity from prior therapy must have recovered to ? Grade 1 (except alopecia).Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention in the opinion of the principal investigator prior to starting therapyXx_NEWLINE_xXExisting severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity > grade 3 except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from total parenteral nutrition (TPN), which may be grade 3Xx_NEWLINE_xXThe risk factor for RVO are listed below; exclusion should be considered by clinical discretion if they have the following conditions:\r\n* Uncontrolled glaucoma with intra-ocular pressures > 21 mmHg\r\n* Serum cholesterol >= grade 2\r\n* Hypertriglyceridemia >= grade 2\r\n* Hyperglycemia >= grade 2Xx_NEWLINE_xXHas had prior chemotherapy within 3 weeks, or targeted small molecule therapy or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: subjects with any grade alopecia are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXUnresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure excluding alopeciaXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first dose of MK-3475 or has not recovered (i.e., to =< grade 1 or baseline) from adverse events due to a previously administered agent; Note, subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note, if a subject received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovered (returned to ? grade 1 as per CTCAE v4.03) from prior treatment-related toxicity.Xx_NEWLINE_xXToxicities from previous cancer therapies resolved to =< grade 1 unless specified otherwise in the inclusion or exclusion criteria (Exceptions: Chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of pemetrexed and sorafenib, such as alopecia, changes in pigmentation, stable endocrinopathies; neuropathy related to previous chemotherapy must be resolved to =< grade 2)Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)\r\n* Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXPrior auto graft is allowed prior to study start (1st dose of study medication), but patients must be at least 3 months from date of stem cell infusion and have recovered to =< grade 1 toxicities related to this procedureXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, radiation or other anti-cancer therapy (with exceptions for certain disease-specific hormone and other treatments) within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior grade ? 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved immune related adverse events (irAE) > grade 1Xx_NEWLINE_xXGrade >= 3 non-hematologic toxicity from previous therapy that has not resolved to =< grade (G)1Xx_NEWLINE_xXChemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubjects who are receiving any concurrent investigational or conventional agent with known or suspected activity against multiple myeloma, or those whose adverse events due to agents administered more than 4 weeks earlier have not recovered to a severity of grade 0 or grade 1; subjects with chronic grade 2 toxicities may be eligible per discretion of the investigator and M. D. Anderson Cancer Center (MDACC) Investigational New Drug (IND) Office (eg, grade 2 chemotherapy-induced neuropathy)Xx_NEWLINE_xXToxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1 (except for alopecia);Xx_NEWLINE_xXToxicities from prior therapies, with the exception of peripheral neuropathy attributable to bortezomib, must have recovered to grade =< 2 according to the Common Toxicity Criteria (CTC) 4.0 criteria or to the subject’s prior baselineXx_NEWLINE_xXCOHORT I: Non-bevacizumab failure, i.e. either no prior bevacizumab or bevacizumab stable/responder, which is defined as stable for at least 6 months from prior treatment with bevacizumab without experiencing a bevacizumab adverse event of special interest (AESI) while on a bevacizumab-containing regimen, such as:\r\n* >= grade 3 hypertension not controlled by medication, hypertensive crisis, or hypertensive encephalopathy\r\n* >= grade 3 proteinuria that does not resolve or nephrotic syndrome\r\n* Any grade gastrointestinal (GI) perforation\r\n* >= grade 3 infusion-related reaction\r\n* >= grade 3 wound healing complications\r\n* >= grade 3 hemorrhage or any grade central nervous system (CNS) hemorrhage or >= grade 2 hemoptysis\r\n* Any grade arterial thromboembolic event (e.g. myocardial infarction or cerebral infarction) or >= grade 3 venous thromboembolic event\r\n* Any grade posterior reversible encephalopathy syndrome (PRES)\r\n* >= grade 3 congestive heart failure\r\n* >= grade 2 non-GI abscesses and fistulaeXx_NEWLINE_xXResolution of all treatment-related toxicities, except alopecia, anemia and neuropathy, from any previous cancer therapy to ? Grade 1 prior to the first dose of study treatment.Xx_NEWLINE_xXProteinuria < grade 2Xx_NEWLINE_xXGrade >= 3 non-hematologic toxicity from previous therapy that has not resolved to =< grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks (6 weeks for nitrosureas or mitomycin C) prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy and be at least 28 days from surgeryXx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2, prior platinum-therapy related neuropathy.Xx_NEWLINE_xXPatients must have recovered from all toxicities related to prior anticancer therapies to grade ? 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.Xx_NEWLINE_xXPatients with low grade glioma are not eligibleXx_NEWLINE_xXHave received anti-cancer therapies listed below within the specified timeframe, or who have ongoing toxicity from prior therapy > Grade 1 according to the Common Terminology for Adverse Events (CTCAE). Exceptions to this are: > Grade 1 toxicities which in the opinion of the Investigator should not exclude the subject (e.g. alopecia, Grade 2 neuropathy, hypo- or hyperthyroidism or other endocrinopathies that are well-controlled with hormone replacement) and are approved by the Medical Monitor.Xx_NEWLINE_xXAt least 4 weeks from end of surgery, chemotherapy, or radiotherapy with resolution of any toxicity to grade 1 or less, excluding alopecia\r\n* NOTE: There is no washout for patients who have undergone cosmetic surgeriesXx_NEWLINE_xXSubject has unresolved adverse events >= Grade 2 from prior anticancer therapy, except for alopecia or anemia.Xx_NEWLINE_xXMust not have had a grade >= 3 immune related adverse event (irAE) on nivolumab monotherapy (excluding endocrine toxicity managed with replacement therapy)Xx_NEWLINE_xXGrade >= 3 nonhematological toxicity from prior therapy that has not resolved to =< grade 1Xx_NEWLINE_xXAny unresolved toxicity > CTCAE grade 2 despite optimal care/support, from previous anti-cancer therapy, except for alopecia, within 7 days prior to Cycle 1, day 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to lymphodepletion or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy, alopecia, hypophysitis stable on physiologic dose of steroid equivalent to prednisone < 10 mg/day, hypothyroidism stable on hormone replacement are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients must be at least 4 weeks from any prior treatments and have recovered (to < grade 2) from acute toxicity attributed to this prior treatment, unless considered chronicXx_NEWLINE_xXPersistent toxicities (> CTCAE grade 2) with the exception of alopecia, caused by previous cancer therapyXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nToxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE v 4.03 except hemoglobin; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the PIXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade 1 as per National Cancer Institute (NCI)-CTCAE v4.0; patients with greater than 1+ proteinuria at entry are ineligibleXx_NEWLINE_xXPHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade 1 as per NCI-CTCAE v4.0; patients with greater than 1+ proteinuria at entry are ineligibleXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nToxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE v 4.03 except hemoglobin; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the PIXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade 1 as per NCI-CTCAEv4.0Xx_NEWLINE_xXPHASE II STUDY NON-SMALL CELL LUNG CANCER (COHORT 2; MEDI+O AND MEDI+C) AND SMALL CELL LUNG CANCER (COHORT 3; MEDI+O ONLY) ELIGIBILITY CRITERIA:\r\nAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade 1 as per NCI-CTCAEv4.0; patients with greater than 1+ proteinuria at entry are ineligibleXx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nThe patient has not recovered to baseline or CTCAE =< grade 1 from toxicity due to all prior therapies, including surgery, except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nToxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE v 4.03 except hemoglobin; patients with long-standing stable grade 2 neuropathy may be considered after discussion with the PIXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1; toxicities of prior therapy, excepting alopecia, should be resolved to less than or equal to grade 1 as per NCI-CTCAEv4.0; patients with greater than 1+ proteinuria at entry are ineligibleXx_NEWLINE_xXNo toxicities related to prior treatment related toxicities with the exception of alopecia and neuropathyXx_NEWLINE_xXTo be eligible for study treatment, toxicity from prior treatment must recover to Grade ? 1, except for alopeciaXx_NEWLINE_xXNon-hematologic toxicities from previous cancer therapies resolved to =< grade 1 except chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of regorafenib and sildenafil (eg, alopecia, changes in pigmentation, stable endocrinopathies)Xx_NEWLINE_xXSubject has recovered from toxicities of prior chemotherapy or other therapy (to grade 2 or less)Xx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubject has had prior chemotherapy, targeted small molecule therapy, 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; note: subjects with =< grade 2 neuropathy are an exception to this criterionXx_NEWLINE_xXPatients must have recovered from acute non hematologic toxicity (to =< grade 1) of all previous therapy prior to enrollmentXx_NEWLINE_xXThere is no restriction on the number of prior therapies allowed for this disease and prior radiation and chemotherapy is allowed, provided the subject has recovered from all grade 2 or greater toxicity prior to enrollmentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; prior radiation does not require a washout period; note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXNon-hematological toxicities ? Grade 2Xx_NEWLINE_xXActive GVHD grade ? 2Xx_NEWLINE_xXDiarrhea > grade 1 in the absence of anti-diarrhealsXx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with alopecia or =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovery from >= grade 2 toxicities of prior therapy regimen to grade 1 or baseline, with the exception of anemia and lymphopenia and chronic residual toxicities that in the opinion of the investigator are not clinically relevant given the known safety/toxicity profiles of gemcitabine, sorafenib, and vorinostat (eg, alopecia, changes in pigmentation, stable endocrinopathies); patients with =< grade 2 peripheral sensory or motor neuropathy are eligibleXx_NEWLINE_xXRecurrent high grade gliomaXx_NEWLINE_xXNot recovered from toxicity of any prior chemotherapy to grade ? 1.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to NCI-CTCAE v4, Grade =<1 or baseline. Subjects with chronic Grade 2 toxicities may be eligible per discretion of the Investigator and Sponsor (eg, Grade 2 chemotherapy-induced neuropathy).Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to day 1 drug administration on study or inability to recover (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy or alopecia are exceptions to this criterion and may qualify for the study\r\n* Note: If subject had major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients who have not recovered from acute non hematologic toxicity (to =< grade 1) of all previous therapy prior to enrollmentXx_NEWLINE_xXSubject has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent;\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXThe subject has not recovered to baseline or CTCAE =< grade 1 from toxicity due to all prior therapies except alopecia and other non-clinically significant adverse events (AEs)Xx_NEWLINE_xXAll prior treatment-related toxicities must be =< grade 1Xx_NEWLINE_xXPersistent toxicities >= grade 2 from prior chemotherapy or biological therapy regardless of interval since last treatmentXx_NEWLINE_xXAll adverse events grade =< 2 related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved, except for alopecia or neuropathy; patients are eligible for enrollment if they have had no surgery in the prior 6 weeks (minor surgical procedures such as skin biopsies and port placement done on an outpatient basis do not require a waiting period)Xx_NEWLINE_xXAll toxicities from prior therapy must be recovered to a grade 1 or better according to the Clavien-Dindo classification systemXx_NEWLINE_xXPatients who have residual toxicity(-ities) from previous anti-cancer treatment(s) that is/are clinically significant or > grade 1 are excluded; those whose toxicity(-ities) improved to grade 1 or better will be eligibleXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving immunotherapy (including anti-cytotoxic T-lymphocyte antigen 4 [CTLA-4] or anti-cluster of differentiation [CD]137 monoclonal antibody [MAb]) or any unresolved irAE of any grade (controlled irAE endocrinopathies are allowed)Xx_NEWLINE_xXNo diarrhea >= grade 2 at baselineXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia); any immuno-oncology (IO) related adverse events must be =< grade 1 to be eligibleXx_NEWLINE_xXAny clinically significant toxicity from prior therapy must have improved to grade 0 or grade 1Xx_NEWLINE_xXSkin toxicity no greater than grade 1Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); patients must have progressing disease after prior treatment; note: patients who have previously received ipilimumab and have documented gastrointestinal (GI) toxicity must have a normal colonoscopy with normal colonic biopsiesXx_NEWLINE_xXToxicity related to prior therapy must either have returned to =< grade 3, baseline, or deemed irreversibleXx_NEWLINE_xXNon-hematological toxicity related to prior therapy must either have returned to =< grade 3, baseline, or deemed irreversibleXx_NEWLINE_xXChemotherapy or radiotherapy within 4 weeks prior to entering the study or those with residual treatment related toxicity of greater than grade 1 not addressed in inclusion criteriaXx_NEWLINE_xXPresence of an acute or chronic toxicity of prior chemotherapy that has not resolved to ? Grade 1, as determined by CTCAE v 4.0.Xx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXPatient who has had chemotherapy, radioactive, or biological cancer therapy within four weeks prior to the first dose of study drug, or who has not recovered to CTCAE grade 1 or better from the AEs due to cancer therapeutics administered more than four weeks earlier; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parameters defined in the inclusion criterion aboveXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); patients must have progressing disease after prior treatmentXx_NEWLINE_xXPrior grade 4 toxicity attributed to cytarabineXx_NEWLINE_xXExisting severe major organ dysfunction, i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade 3, except for grade 3 hematologic toxicityXx_NEWLINE_xXTreatment-related toxicities from prior therapies must have resolved to grade =< 1Xx_NEWLINE_xXAt least 4 weeks since prior surgery with full recovery (no persistent toxicity >= grade 1)Xx_NEWLINE_xXRecovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy to the lung or brain within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; previous radiation to other sites may be completed at any time prior to initiation of MK-3475\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: toxicity that has not recovered to =< grade 1 is allowed if it meets the inclusion requirements for laboratory parametersXx_NEWLINE_xXPatients will be eligible if the original histology was low-grade glioma and a subsequent histological diagnosis of a high grade glioma is madeXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXNewly diagnosed supratentorial brain lesion compatible with a high grade glioma (WHO III or IV) by magnetic resonance (MR) with no prior treatment with either gene therapy, chemotherapy or radiation treatments that is amenable to attempted gross total resection (GTR); “high grade glioma” can include: glioblastoma multiforme (WHO grade IV); anaplastic astrocytoma (WHO grade III); anaplastic oligodendroglioma (WHO grade III); and anaplastic ependymoma (WHO grade III)Xx_NEWLINE_xXMore than one grade 2 or higher transaminase elevationXx_NEWLINE_xXPatients MUST have recovered from all treatment related toxicities to Grade 1 NCI CTCAE (v 4.0) in severityXx_NEWLINE_xXPatients must have recovered all toxicities from prior therapy or radiation to grade 1 or less (excluding alopecia).Xx_NEWLINE_xXTreatment-related toxicities from prior therapies must have resolved to grade equal to or less than 1Xx_NEWLINE_xXGrade >= 3 non-hematologic toxicity from previous therapy that has not resolved to =< grade 1Xx_NEWLINE_xXPatient who has had radiotherapy within 1 week (or unresolved radiation-related toxicities), chemotherapy within 2 weeks or 5 half-lives, whichever is longer (6 weeks for nitrosoureas, mitomycin C or bevacizumab), anti-cancer monoclonal antibody for direct anti-neoplastic treatment within 3 weeks, or who has not recovered from toxicity due to previous agents administered. If the patient has residual toxicity from prior treatment, toxicity must be =< grade 1 (except for neuropathy and alopecia)Xx_NEWLINE_xXNo active acute GvHD >= grade IIXx_NEWLINE_xXAny previous history of >= grade 3 toxicity to dasatinibXx_NEWLINE_xXIf the patient has residual toxicity from prior treatment, toxicity must be =< grade 1Xx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXPatients with a history of any grade of persistent or chronic nausea or vomiting within the last 4 weeks related to prior therapy or disease processXx_NEWLINE_xXPrior neurologic toxicity to previous immunotherapyXx_NEWLINE_xXAny unresolved toxicity ? Grade 2 from previous anticancer therapy except for stable chronic toxicities (? Grade 2) not expected to resolve.Xx_NEWLINE_xXAll irAEs while receiving prior immunotherapy must have resolved to ? grade 1 or Baseline prior to Screening for this study. Must not have experienced a ? grade 3 immune-related AE within the past 16 weeks or any grade 4 life- threatening irAE (regardless of duration) or neurologic or ocular AE of any grade while receiving prior immunotherapy (NOTE: Subjects with endocrine AE of any grade are permitted to enroll if they are stably maintained on appropriate replacement therapy, but must have no history of adrenal crisis and be asymptomatic)Xx_NEWLINE_xXExperiencing CTCAE grade >1 events, experienced immune-related grade ?3AEs with prior immunotherapyXx_NEWLINE_xXRecovery to Grade 1 of any clinically significant toxicity attributed to prior anticancer therapy prior to initiation of study drug administrationXx_NEWLINE_xXAll acute toxicities from prior therapy with the exception of alopecia must have resolved to =< grade 1Xx_NEWLINE_xXSevere major organ toxicity: specifically, renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 2 or less; a grade 3 hearing deficit is acceptableXx_NEWLINE_xXAt least 28 days elapsed between last anti-cancer treatment administration and the initiation of study treatment (except for Luteinizing Hormone-releasing Hormone [LHRH] or Gonadotropin-releasing Hormone [GnRH]), or resolution of all previous treatment related toxicities to CTCAE version 4.03 grade of ? 1 (except for chemotherapy induced alopecia and grade 2 peripheral neuropathy or grade 2 urinary frequency which are allowed). Prior major surgery must be at least 12 weeks prior to study entry.Xx_NEWLINE_xXPatients with unresolved > Grade 1 toxicity associated with any prior antineoplastic therapyXx_NEWLINE_xXToxicity from previous treatment including: a) Toxicity Grade >=3 related to prior immunotherapy and that lead to study treatment discontinuation. b) Toxicity related to prior treatment has not resolved to Grade <=1 (except alopecia, or endocrinopathy managed with replacement therapy).Xx_NEWLINE_xXHas had a prior monoclonal antibody (mAb) within 4 weeks prior to Study Day 1 or who has not recovered (i.e. ? Grade1 1 or at baseline) from acute adverse events from prior mAb therapy NOTE: Subjects with ? Grade 2 neuropathy or Grade 2 alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed;Xx_NEWLINE_xXHas had chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events due to a previously administered agent NOTE: Subjects with ? Grade 2 neuropathy or Grade 2 alopecia are an exception to this criterion and may qualify for the study. Investigators should discuss individual cases with the Medical Monitor or Sponsor as needed; orXx_NEWLINE_xXHas not recovered from prior surgery, chemotherapy or radiation therapy from adverse events due to a previous treatment/administered agent (i.e., =< grade 1 or return to baseline prior to treatment)\r\n* Note: subjects with =< grade 2 neuropathy, any grade hearing loss or tinnitus, or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny unresolved toxicities from prior therapy greater than CTCAE grade 1 at the time of starting study treatment with the exception of alopecia and grade 2, prior platinum-therapy related neuropathyXx_NEWLINE_xXHistory of immune-related adverse event from prior immunotherapy treatment that has not improved to grade 0-1; subjects with grade 2 hypothyroidism and grade 2 adrenal insufficiency requiring continued medical treatment may enroll provided that they are asymptomatic and stable on their dose of hormone replacementXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer treatment that, in the judgement of the investigator, may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must resolve to grade 1 (NCI CTCAE version 4) or baseline prior to enrollment. Eligible patients must not require more than 10 mg/day prednisone (or equivalent dose).Xx_NEWLINE_xXRecovered from toxicities of previous anticancer therapy to CTCAE Grade ? 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 14 days prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from AEs due to a previously administered agent.Xx_NEWLINE_xXRecovered from all toxicities related to prior anti-cancer therapies to grade ? 1Xx_NEWLINE_xXRecovered from toxicities of previous anticancer therapy to CTCAE Grade ? 1 with the exception of alopeciaXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 2 or at baseline) from adverse events due to a previously administered agent; Note: If the subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXClinical relevant AEs or laboratory results related to previous anti-neoplastic therapy have not resolved to a NCI-CTCAE grade ?1.Xx_NEWLINE_xXHistology other than astrocytoma grade IVXx_NEWLINE_xXRecovery to Grade 1 or baseline of any toxicities due to prior treatments, excluding alopeciaXx_NEWLINE_xXConfirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosisXx_NEWLINE_xXOtherwise, all toxicity at study entry ? Grade 1 by NCI CTC v4.0.Xx_NEWLINE_xXComplex stenoses (Bismuth grade IV) will not be eligible for the trialXx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXPast discontinuation of bortezomib due to associated grade 3 or higher adverse eventXx_NEWLINE_xXAny grade 3-4 adverse event related to HSV-Tk infusion or a grade 2 adverse event that does not resolve to no more than grade 1 before the next infusionXx_NEWLINE_xXTreatment with chemotherapy or investigational drugs within 21 days prior to the screening visit. Acute toxicities from prior therapy must have resolved to Grade ? 1 above baseline.Xx_NEWLINE_xXRecovered from all acute toxicities caused by prior cancer therapies, except for alopecia.Xx_NEWLINE_xXSubjects with neuropathy grade ?2 based on CTCAE v4.03 at the time of study entryXx_NEWLINE_xXPatients with the following histologies: \r\n* Diffuse astrocytoma (grade 2)\r\n* Oligodendrogliomas (any grade)\r\n* Pleomorphic xanthoastrocytoma (PXA, any grade)Xx_NEWLINE_xX208 Unresolved toxicity from prior anti-tumor therapy, defined as not having resolved to CTCAE version 4.0 grade 1, or to levels dictated in the eligibility criteria with the exception of alopecia or toxicities from prior anti-tumor therapy that are considered irreversible (defined as having been present and stable for > 28 days) which may be allowed if they are not otherwise described in the exclusion criteria AND there is agreement to allow by both the investigator and the Amgen Medical Monitor.Xx_NEWLINE_xXPersisting toxicity related to prior therapy Grade >1.Xx_NEWLINE_xXPrior systemic chemotherapy for indications other than urothelial cell carcinoma of the bladder is permitted. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must have resolved to Grade 1 (National Cancer Institute CTCAE version 4.03) or baseline before administration of study drug. Participants with toxicities attributed to prior anti cancer therapy which are not expected to resolve and result in long lasting sequelae, such as peripheral neuropathy after platinum-based therapy or audiometric hearing loss, are permitted to enroll.Xx_NEWLINE_xXMust have recovered (? Grade 2 or at pretreatment baseline) from adverse events (AEs) from previously administered therapies except for stable chronic toxicities (? Grade 2) not expected to resolve.Xx_NEWLINE_xXToxicities incurred as a result of previous anti cancer therapy (radiation therapy [RT], chemotherapy, or surgery) must be resolved to ? Grade 1 except for alopecia and anorexia.Xx_NEWLINE_xXGrade > 1 toxicity from prior therapy (except alopecia or anorexia)Xx_NEWLINE_xXUnresolved > Grade 1 toxicity associated with any prior antineoplastic therapyXx_NEWLINE_xXPrior Grade 3 or higher immune-related AEs or any ocular toxicity on prior immunotherapy as per protocol-defined criteria.Xx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy must be resolved to grade ? 1 before enrollment, with the exception of alopecia (any grade permitted), or bone marrow parameters (any grades permitted)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSevere immune-related toxicity related to checkpoint inhibitors defined as any Grade 4 toxicity or Grade 3 toxicityXx_NEWLINE_xXSevere immune-related toxicity related to checkpoint inhibitors defined as any Grade 4 toxicity or Grade 3 toxicityXx_NEWLINE_xXAdverse events resulting from previous therapies have not recovered to grade 1 or lessXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXOtherwise, all acute toxicity at study entry ? Grade 1 by NCI CTC v4.0, or recovered to baselineXx_NEWLINE_xXGrade >= 3 non-hematologic toxicity from prior therapy that has not resolved to =< grade 1 (G1).Xx_NEWLINE_xXGrade > 1 toxicity from prior therapy (except alopecia or anorexia).Xx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopecia.Xx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1)Xx_NEWLINE_xXIf received prior immunotherapy must not have experienced one of the following:\r\n* A toxicity that led to permanent discontinuation of prior immunotherapy\r\n* All adverse events (AEs) while receiving prior immunotherapy must have completely resolved or resolved to baseline prior to screening for this study\r\n* Must not have experienced a >= grade 3 immune related AE or an immune related neurologic or ocular AE of any grade while receiving prior immunotherapy; NOTE: Patients with endocrine AE of =< grade 2 are permitted to enroll if they are stably maintained on appropriate replacement therapy and are asymptomatic\r\n* Must not have required the use of additional immunosuppression other than corticosteroids for the management of an AE and must not have experienced recurrence of an AE if re-challengedXx_NEWLINE_xXInadequate recovery from adverse events related to prior therapy to grade =< 1 (excluding grade 2 alopecia and neuropathy)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., ? grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Subjects with ? grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo). (Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.Xx_NEWLINE_xXAny unresolved toxicity (CTCAE grade < 2) from previous anti-cancer therapy; (subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXAny prior grade >/= 3 immune-related adverse event (imAE) while receiving any previous immunotherapy agent, or any unresolved imAE > grade 1Xx_NEWLINE_xXAny unresolved toxicity (National Cancer Institute Common Terminology Criteria for Adverse Event [CTCAE] version 4.03 [v4.03]) grade 2 or greater from previous anticancer therapy with the exception of alopecia, and the laboratory values defined in the inclusion criterion 8. Hearing loss of grade 3 or lower and peripheral neuropathy of grade 2 or lower is allowed. Subjects with grade >= 2 neuropathy will be evaluated on a case-by-case basis after consultation with the study physician. Subjects with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab may be included only after consultation with the study physician.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXGrade >= 2 proteinuria at screening (or known prior)Xx_NEWLINE_xXFirst or second recurrence of previously histologically confirmed glioblastoma (grade 4 astrocytoma)\r\n* NOTE: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) may be included, primitive neuroectodermal tumor (PNET) variants are excluded; grade 4 oligodendrogliomas or oligoastrocytomas are specifically excludedXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; note: subjects with =< grade 2 neuropathy or alopecia are an exception to this criterion and may qualify for the study; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPresence of any CTCAE grade 2 or greater toxicityXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPatients will be ineligible if they have a baseline neurologic toxicity of grade 3 or greaterXx_NEWLINE_xXPrior treatment within 21 days of the first dose of study drug with any other chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment, or failure to recover from adverse effects of prior therapies administered over 4 weeks prior to study day 1; all toxicities from prior therapies must be =< grade 1 (or =< grade 2 for alopecia or peripheral neuropathy); prior systemic treatment in the adjuvant setting is allowedXx_NEWLINE_xXPatients are eligible if they had a prior low grade astrocytoma that was not previously treated, and there is subsequent histological evidence of a diagnosis of grade III or IV astrocytomaXx_NEWLINE_xXToxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversibleXx_NEWLINE_xXToxicity related to prior therapy must either have returned to less than or equal to grade 1, baseline, or been deemed irreversibleXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXDiarrhea > grade 1 at baselineXx_NEWLINE_xXPatients must demonstrate resolution of all toxicities related to prior chemotherapy, endocrine therapy, or biologic therapy to grade =< 1, including peripheral neuropathy, with the exception of alopecia (any grade permissible)Xx_NEWLINE_xXHearing loss >= grade 2Xx_NEWLINE_xXHas any prior Grade ?3 immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA-4 treatment, or any unresolved irAE >Grade 1.Xx_NEWLINE_xXParticipant must have recovery to Grade 0 or 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administration.Xx_NEWLINE_xXRecovery to baseline or ? Grade 1 CTCAE ver.4.0Xx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 excepting alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy =< 2 weeks prior to registration or who has not recovered to =< grade 1 or baseline from adverse events due to the previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXAll acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n*Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n*Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients must have a creatinine and AST =< grade 1Xx_NEWLINE_xXAST =< grade 1Xx_NEWLINE_xXPatients with ataxia >= CTCAE grade 2 are ineligibleXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1 except for endocrine adverse events (AEs) managed with replacement therapy; any other AEs unresolved toxicities grade 2 or more from previous anti-cancer therapy, except alopecia, peripheral neuropathy or non-clinically significant lab abnormalitiesXx_NEWLINE_xXPatients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1)Xx_NEWLINE_xXNon-hematologic toxicities from previous cancer therapies resolved to =< grade 1Xx_NEWLINE_xXGrade 3-4 electrolyte abnormalities (CTCAE, v. 4):Xx_NEWLINE_xXAny Grade ? 2 persistent non-hematological toxicity related to allotransplantXx_NEWLINE_xXPersisting effects of any previous or ongoing treatment ? grade 1 that might compromise delivery of study treatment or assessment of adverse events (except alopecia or neuropathy ? grade 2 without pain)Xx_NEWLINE_xXDOSE ESCALATION COHORT: Any prior ? grade 3 immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA-4 and anti-PD-1/PD-L1 treatment, or any unresolved irAE > grade 1\r\n* Note: Previous immune-related ocular toxicity of any grade is excludedXx_NEWLINE_xXDOSE EXPANSION COHORT: Any prior ? grade 3 immune-related adverse event (irAE) while receiving immunotherapy, including anti-CTLA-4 and anti-PD-1/PD-L1 treatment, or any unresolved irAE > grade 1; Note: previous immune-related ocular toxicity of any grade is excludedXx_NEWLINE_xXSubjects must have progressive cancer at the time of study entry; prior experimental (non-Food and Drug Administration [FDA] approved) therapies (other than drugs that share the same target) and immunotherapies are allowed; patients must not have received these therapies for 30 days or five half-lives of the drug (whichever is less) prior to the initiation of study treatment; toxicities from these therapies should have recovered to =< grade 1, with the exception of stable chronic grade 2 that is not overlapping with presumed toxicities of olaparibXx_NEWLINE_xXPersistent toxicities caused by previous cancer therapy; toxicities should have recovered to =< grade 1, excluding alopecia and stable chronic grade 2 toxicity that is not overlapping with presumed toxicities of olaparibXx_NEWLINE_xXMajor surgery within 2 weeks of starting study treatment; effects from surgeries should have recovered to =< grade 1, with the exception of stable chronic grade 2 that is not overlapping with presumed toxicities of olaparibXx_NEWLINE_xXPrior therapy including chemotherapy, targeted small molecule therapy or radiation therapy =< 2 weeks prior to registration OR failure to recover (to =< grade 1 or to baseline) from adverse events (AE) attributable to agents received > 4 weeks prior to registration; NOTE: exception for neuropathy =< grade 2, which is allowedXx_NEWLINE_xXAny unresolved toxicity (> CTCAE grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXPatients must have recovered from acute toxicities of prior chemotherapy or stem cell transplant; any prior non-hematologic vital organ toxicity (cardiac, pulmonary, hepatic, renal) of previous therapy must have resolved to grade 1 or lessXx_NEWLINE_xXUnresolved toxicity higher than CTCAE grade 1 attributed to any prior therapy/procedure, excluding alopeciaXx_NEWLINE_xXPrevious toxicities from previous treatment must have resolved to grade 1 or less\r\n* For patients in expansion cohort B, stable grade 2 neuropathy will be allowedXx_NEWLINE_xXPrior treatment-related toxicity resolved to =< grade 1 or baseline with the exception of alopecia and permanent grade =< 2 toxicities related to prior immune checkpoint inhibitor treatment (e.g. PD-1/PD-L1, CTLA-4, CD40, LAG3) treatment with the review and approval by the lead principal investigator (PI)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXToxicities of prior therapy (excepting alopecia) should be resolved to less than or equal to grade 1 as per CTCAE v 4.0Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first protocol treatment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: Patients who have had prior treatments with tyrosine kinase inhibitors (e.g. Tarceva) require only a 72-hour washout period prior to starting protocol treatmentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXResidual adverse events due to previously administered agents (except alopecia, stable residual neuropathy, and residual hand, foot syndrome) that have not recovered to Grade 1 or below in severity level (based on NCI CTCAE) before ScreeningXx_NEWLINE_xXThe patient has not recovered from adverse events related to prior therapy to Grade ?1 (excluding Grade 2 alopecia and neuropathy)Xx_NEWLINE_xXPersistent toxicities >= grade 3 from prior chemotherapy or biological therapy regardless of interval since last treatmentXx_NEWLINE_xXTriglycerides < CTCAE grade 2Xx_NEWLINE_xXResolution of all chemotherapy related grade III-IV toxicityXx_NEWLINE_xX=< grade 2 hematuria (criteria applicable only for dose levels that include isotretinoin) and =< grade 2 proteinuriaXx_NEWLINE_xXSkin toxicity =< grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and/or alopecia are exceptions to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovered from prior toxicities to grade 0-1 at least 2 weeks prior to investigational therapyXx_NEWLINE_xXHas received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment start\r\n* Note: participants must have recovered from all adverse events (AEs) due to previous therapies to =< grade 1 or baseline; participants with =< grade 2 neuropathy may be eligible\r\n* Note: if participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatmentXx_NEWLINE_xXAny patient who has not recovered (i.e., =< grade 1 or at baseline) from adverse events or complications due to a previously administered systemic agent, radiation therapy, or major surgery\r\n* Exceptions: \r\n** Subjects with =< grade 2 neuropathy, hot flashes, or hypertension may qualify for the study if all other eligibility criteria met\r\n** Other toxicity or complications that are deemed by the treating investigator as not clinically significant (e.g., urinary incontinence from past prostatectomy)Xx_NEWLINE_xXPatients must have completed standard therapy for their malignancy and recovered from all toxicities to less than or equal to grade 2 within 3 weeks prior to enrollmentXx_NEWLINE_xXPersistent toxicities (>= CTCAE grade 2) caused by previous cancer therapyXx_NEWLINE_xXAny toxicity related to prior EGFR inhibitor treatment must have resolved to Grade 1\n             or lessXx_NEWLINE_xXPatients who have had chemotherapy, targeted therapy, or radiotherapy, and have not recovered from acute toxicity to their pretreatment baseline or to a grade 1 level within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study \r\n* Note: patients with chronic residual prior therapy-related toxicity (e.g. vitiligo, alopecia, low grade neuropathy), or in the consensus opinion of the Cancer Immunotherapy Trials Network (CITN)/Cancer Therapy Evaluation Program (CTEP) investigators would not impact the safety of the patient or the integrity of the study, are not excluded\r\n* Note: for resolution of autoimmune toxicity from prior immune therapy, patients must be off steroids for at least 30 days without relapse of autoimmune toxicity, or it must be at least 30 days from their last dose of infliximab or related immunosuppressive therapy without relapse of autoimmune toxicityXx_NEWLINE_xXDehydration grade >= 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubjects experiencing unresolved toxicity of previous antitumor therapy which is CTCAE grade > 1 before the start of study treatment, except for alopecia or hemoglobin >= 9.0 g/dL or >= 5.6 mmol/LXx_NEWLINE_xXGrade 2 or greater toxicity from prior therapyXx_NEWLINE_xXRecovery to =< grade 1 toxicities associated with prior therapyXx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopeciaXx_NEWLINE_xXHas had prior monoclonal antibody, chemotherapy (including dexamethasone for multiple myeloma [MM] treatment), targeted small molecule therapy, or radiation therapy within 2 weeks prior to transplant admission (or ~4 weeks prior to the first dose of MK-3475); OR has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agent more than 2 weeks prior to transplant admission or more than 4 weeks prior to the first dose of MK-3475; NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to transplant admission; NOTE: Toxicity that has not recovered to =< grade 1 is allowed if it meets the requirements per institutional guidelines for high-dose melphalan and autologous transplantXx_NEWLINE_xXPrevious cytotoxic chemotherapy must have been completed at least 3 weeks and radiotherapy at least 2 weeks prior to day 1 of treatment on the study and all adverse events (excluding alopecia, acne, rash) due to agents administered more than 3 weeks earlier should have recovered to =< grade 1; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (adverse event [AE]) and do not need to resolve to =< grade 1Xx_NEWLINE_xXAt least 14 days must have elapsed since any prior systemic therapy at the time the patient starts the cyclophosphamide and fludarabine (fludarabine phosphate) conditioning regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)Xx_NEWLINE_xXSubjects who experienced grade 3 or 4 toxicity regardless of causality to the cell infusion must have had a reduction to a grade 1 or less or returned to baseline levelsXx_NEWLINE_xXAll prior treatment-related toxicities must be CTCAE v4 grade =< 1 (except alopecia) at the time of randomizationXx_NEWLINE_xXPatients must have recovered from all non-hematologic toxicities to =< grade 2 and from all hematologic toxicities to =< grade 3 prior to registrationXx_NEWLINE_xXPatients with pre-existing grade 2 or higher neuropathy or other serious neurologic toxicity that would significantly increase risk of complications from bortezomib therapy are excludedXx_NEWLINE_xXRecovered from any toxicity to grade 2 or less from all prior chemotherapy, immunotherapy or radiotherapy and be at least 30 days past the date of their last treatment with the exception of mitotane which may be continuedXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteriaXx_NEWLINE_xXPrior chemoembolization, local ablative therapies, or hepatic resection permitted if completed >= 4 weeks prior to study enrollment if patient has recovered with =< grade 1 toxicity and if measurable disease is presentXx_NEWLINE_xXAt least 12 weeks beyond stem cell transplant and 4 weeks beyond chemotherapy or\n             immunotherapy, major surgery, other experimental treatments, or radiation therapy to\n             the index lesions, and with all acute toxicities from prior therapy resolved to less\n             than Grade 2 toxicity by NCI CTC version 4.0Xx_NEWLINE_xX< Grade 3 hypo/hyperphosphatemiaXx_NEWLINE_xX< Grade 3 hypo/hypermagnesemiaXx_NEWLINE_xXActive diarrhea >= CTCAE grade 2Xx_NEWLINE_xXOmission of cytotoxic chemotherapy or other systemic therapy of the malignancy for >= 4 weeks prior to entry into the trial; patients must be >= 4 weeks since major surgery, radiotherapy, or biotherapy/targeted therapies and recovered from the toxicity of prior treatment to =< Common Toxicity Criteria (CTC) grade 1, exclusive of grade 2 alopecia, fatigue, lymphopenia, CD4+ circulating T cells, white blood count (WBC) or bilirubinXx_NEWLINE_xXResolution of grade >= 2 toxicity from prior therapy (other than alopecia)Xx_NEWLINE_xXAll previous intravenous therapy administered outside of the National Institute of Health (NIH) Clinical Center must be completed at least 2 weeks prior to study entry, with recovery to =< non-hematologic grade 2 toxicity of previous therapyXx_NEWLINE_xXPersistent, clinically significant > Grade 1 non-hematologic toxicity from prior AML therapy.Xx_NEWLINE_xXRecovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug administrationXx_NEWLINE_xXHas not recovered adequately (i.e., Grade ?1 or baseline) from the toxicity and/or complications from any intervention prior to starting study drug.Xx_NEWLINE_xXSubject has any other organ dysfunction (CTCAE version 4.03 Grade 4) that will interfere with the administration of the therapy according to this protocol.Xx_NEWLINE_xXDiagnosis of WHO Grade IV glioblastoma or WHO Grade III anaplastic gliomasXx_NEWLINE_xXHistory of significant intolerance to capecitabine or fluorouracil (5FU) (ie. grade 4 toxicity related to one of these agents; grade 3-4 toxicity related to other concurrently administered agents is not an exclusion)Xx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is greater than grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXHas not recovered (i.e., AE ? Grade 1 or at Baseline) from AEs due to a previously administered agent.Xx_NEWLINE_xXPersisting toxicity related to prior therapy except alopeciaXx_NEWLINE_xXPatients must not have any known, persistent (> 4 weeks), ?Grade 3 hematologic toxicity during the last cancer therapy. Patients must not have any known, persistent (>4 weeks), ? Grade 3 fatigue during the last cancer therapy.Xx_NEWLINE_xXCurrent grade >= 1 toxicity (except alopecia) from prior therapyXx_NEWLINE_xXFailure to recover (to CTCAE Version 4.0 Grade 0 or Grade 1) from acute non hematologic toxicity (except all grades of alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.Xx_NEWLINE_xXAdverse events from prior anti-cancer therapy that have not resolved to Grade less than or equal to (</=) 1 except for alopecia or endocrinopathy managed with replacement therapyXx_NEWLINE_xXResolution of any adverse events (AEs) from prior treatments must be resolved to baseline or grade =< 1 at enrollment (with the exception of alopecia), neuropathy, and ototoxicity (i.e., AEs that are not expected to improve within the washout period)Xx_NEWLINE_xXGrade 3 or 4 immune related toxicity associated with prior ipilimumab therapy that has not resolved to grade 0 or 1Xx_NEWLINE_xXActive diarrhea of any gradeXx_NEWLINE_xXCytotoxic chemotherapy or radiotherapy within 3 weeks prior and any encountered treatment-related toxicities (excepting alopecia) not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].Xx_NEWLINE_xXMonoclonal antibodies within 4 weeks prior and any encountered treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].Xx_NEWLINE_xXInvestigational drugs (small molecules or biologics) within the longer of 2 weeks or 5 half-lives prior to study treatment and any encountered treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase 2].Xx_NEWLINE_xXRecovery (ie, to Grade 1 or baseline) from all clinically significant AEs related to prior therapies (excluding alopecia, neuropathy, and nail changes)Xx_NEWLINE_xXSubjects who have not recovered to within one grade level (not to exceed grade 2) of their baseline following a significant adverse event or toxicity attributed to prior anti-cancer treatment are excludedXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia)Xx_NEWLINE_xXThe patient has persistent clinically significant toxicities Grade ? 2 from previous chemotherapy (excluding alopecia, nausea, fatigue, and liver function tests (as mandated in the inclusion criteria)).Xx_NEWLINE_xXExcept for alopecia, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study treatment.Xx_NEWLINE_xXAll prior treatment-related toxicities must be CTCAE v4 grade =< 1 (except alopecia) at the time of randomizationXx_NEWLINE_xXKnown persistent (> 4 weeks) ? Grade 2 neutropenia, ? Grade 2 thrombocytopenia or > Grade 3 anemia from prior cancer therapyXx_NEWLINE_xXGrade 3 colitis, hepatitis, pneumonitis uveitis, myocarditis, myositis, CNS toxicity or autoimmune related neuromuscular toxicity such as myasthenia gravis associated with the administration of an immune checkpoint inhibitorXx_NEWLINE_xXPatients must not have any prior grade >= 3 immune-related adverse event (irAE) or any unresolved irAE > grade 1Xx_NEWLINE_xXPatients must not have any prior grade >= 3 immune-related adverse event (irAE) or any unresolved irAE > grade 1 (MEDI4736 RE-TREATMENT)Xx_NEWLINE_xXSubject has any unresolved toxicity Grade > 1 from previous anti-cancer therapyXx_NEWLINE_xXPatients must have completed any prior chemotherapy, radiotherapy or major surgery at least 4 weeks before receiving study treatment; ongoing toxicities related to treatment must be =< grade 1 and patients with grade 2 alopecia or peripheral neuropathy can also be included; palliative radiation to < 10% of bone marrow is permissible if completed within one week of commencing study treatment as long as the toxicities secondary to palliative radiotherapy are limited to grade 1; the lesions that have received radiation treatment immediately before will be excluded as target lesions; previously irradiated lesions can be considered as targeted lesions, as long as there is prove of radiological progressionXx_NEWLINE_xXOngoing toxicity due to a prior therapy, unless returned to baseline or Grade 1. Grade 2 toxicities (e.g., alopecia or peripheral neuropathy) that are not likely to increase the subject's safety risk while receiving trial treatment may be accepted after Sponsor approval.Xx_NEWLINE_xXMinimal or no ongoing toxicity from immediately prior therapy according to specific appropriate criteria. Mild ongoing toxicity is allowed in case of alopecia, skin toxicity, fatigue and/or finger numbness or tumbling.Xx_NEWLINE_xXAdverse event due to cancer therapy administered more than 28 days prior to enrollment that has not recovered to CTCAE grade 1 or better.Xx_NEWLINE_xXAcute toxicities of prior treatments and procedures not resolved to grade ? 1 or baseline before randomisation.Xx_NEWLINE_xXAdverse events from prior anti-cancer therapy that have not resolved to Grade <= 1 except for alopeciaXx_NEWLINE_xXAll prior treatment- related toxicities must be CTCAE (Version 4.0) <=Grade 1 (except alopecia and peripheral neuropathy) at the time of treatment allocation [NCI-CTCAE, 2009].Xx_NEWLINE_xXNo neurosensory or neuromotor toxicity >= grade 2 at the time of registrationXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks (12 weeks for measurable sites of CNS disease) prior to study Day 1 or not recovered from adverse events (improved to grade 1 or less) due to a previously administered agent\r\n* Note: Subjects with neuropathy or =< grade 2 alopecia are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXComplete resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the subject received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to a previously administered agent .Xx_NEWLINE_xXRecovered from toxicities related to prior anticancer therapy to NCI CTCAE v 4.0 grade ?1.Xx_NEWLINE_xXResolution of all toxicities related to prior therapies to ? NCI-CTCAE Grade 1 severity, except for alopecia, vitiligo, or endocrinopathies on replacement therapy.Xx_NEWLINE_xXToxicity from previous anti-cancer therapy that has not recovered to ?Grade 1 prior to enrollment (except for non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with existing pneumonitis as a result of radiation are not excluded; however, subjects cannot be oxygen dependent.Xx_NEWLINE_xXNo ongoing toxicity from prior anti-cancer treatment that may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must resolve to grade 1 or baseline before administration of the study treatment.Xx_NEWLINE_xXAll acute treatment-related toxicity must have resolved to Grade less than or equal to (</=) 1 or be deemed stable by the InvestigatorXx_NEWLINE_xXAll AEs resulting from prior chemotherapy, surgery, or radiotherapy, must have resolved to at least NCI-CTCAE (v. 4.03) Grade 1 (except for laboratory parameters outlined below).Xx_NEWLINE_xXUncontrolled chronic diarrhea ? grade 2 at baseline.Xx_NEWLINE_xXPatients must have recovered (to baseline/stabilization) from prior chemo- or radio-therapy and associated acute toxicities must have resolved to a NCI CTCAE v4 Grade 1 or less, with the exception of alopeciaXx_NEWLINE_xXThe subject has adequately recovered from toxicities due to prior therapy.Xx_NEWLINE_xXRecovery to ? Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;Xx_NEWLINE_xXPrior history of >= grade 2 neurotoxicity or any other toxicity requiring discontinuation of taxane therapy that has not resolved to =< grade 1, with the exception of alopeciaXx_NEWLINE_xXGrade 3 or 4 toxicity related to prior VEGFR TKI that did not resolve to grade 1Xx_NEWLINE_xXAny unresolved toxicity greater than Common Toxicity Criteria (CTC) grade 1 from previous anti-cancer therapyXx_NEWLINE_xXPatients must have recovered from all infectious and non-hematologic toxicities from prior chemotherapy to =< CTCAE grade 1 or baseline prior to study enrollmentXx_NEWLINE_xXResolution of all toxicities and any toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia). Subjects with ? Grade 2 neuropathy are an exception and may enroll.Xx_NEWLINE_xXNeuroendocrine tumors, pancreatic basket\r\n* Grade 1 or grade 2 (or described as low grade, intermediate grade, well differentiated, or moderately differentiated) according to reviewing pathologist\r\n* Progressive disease over the preceding 12 months\r\n* Any number of prior therapies, including 0\r\n* Patients using a somatostatin analogue for symptom control must be on stable doses for 56 days prior to enrollmentXx_NEWLINE_xXNeuroendocrine tumors, extrapancreatic basket\r\n* Grade 1 or grade 2 (or described as low grade, intermediate grade, well differentiated, or moderately differentiated; typical or atypical carcinoid if originating in lung) according to reviewing pathologist\r\n* Progressive disease over the preceding 12 months\r\n* Any number of prior therapies, including 0\r\n* Patients using a somatostatin analogue for symptom control must be on stable doses for 56 days prior to enrollmentXx_NEWLINE_xXAt least a two-week washout period since the end of the last therapy (six weeks for a prior nitrosourea-containing regimen), recovery to grade ? 1 from any non-hematological adverse event (AE) derived from previous treatment (excluding alopecia).Xx_NEWLINE_xXAll acute toxic effects of any prior antitumor therapy resolved to Grade ? 1 before the start of study drug dosing (with the exception of alopecia [Grade 1 or 2 permitted] and neurotoxicity [Grade 1 or 2 permitted])Xx_NEWLINE_xXAny unresolved toxicity > Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy)Xx_NEWLINE_xXhave discontinued all previous treatments for cancer and recovered from the acute effects of therapy, other than less than or equal to Grade 2 neuropathy or nonserious and nonlife-threatening toxicities such as alopecia, altered taste, and nail changesXx_NEWLINE_xXAny prior Grade ? 3 immune-related adverse event (irAE) or any prior corticosteroid-refractory irAEXx_NEWLINE_xXHas not recovered from adverse events to ? Grade 1 or prior treatment level due to a previously administered agentXx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v 4.03 < Grade 2 or normalized to baseline, or to levels dictated in the inclusion/exclusion criteria, with the exception of alopecia.Xx_NEWLINE_xXPrior surgical treatment for prostate cancer is allowed but must have been completed at least 14 days prior to registration and any toxicity from such therapy must have recovered to ? grade 1 per CTCAE version 4 criteria by the time of registration.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXGrade >1 toxicity from prior therapy (except alopecia or anorexia).Xx_NEWLINE_xXCurrent Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior therapyXx_NEWLINE_xXAll treatment-related or radiation-related toxicities resolved to Grade 1 or lowerXx_NEWLINE_xXLack of recovery from all toxicity from previous therapy to grade 1 or baselineXx_NEWLINE_xXPer good clinical practice, any toxicity related to prior therapies that, in the opinion of the investigator, would potentially be worsened with anti-programmed death 1 (PD1) therapy should be resolved to less than grade 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Patients may continue on ovarian suppressionXx_NEWLINE_xXUncontrolled grade 2 or greater toxicity except alopeciaXx_NEWLINE_xXPatients have not recovered from all toxicities related to prior anticancer therapies to grade ?1 (CTCAE v 4.03)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ?Grade 1 or at baseline) from adverse events due to a previously administered agent.Xx_NEWLINE_xXPatients with recurrent WHO grade III gliomas should have received one prior treatment for recurrent high grade diseaseXx_NEWLINE_xXPresence of grade 3 or greater toxicity from the previous treatmentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\nNote: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXPatients must have recovered from all reversible toxicities related to prior therapy before beginning protocol treatment, and may not have any pre-existing treatment-related toxicities greater than grade 2; patients must have < grade 2 pre-existing peripheral neuropathyXx_NEWLINE_xXGrade 3-4 adverse event (AE) associated with prior anti-VEGF therapy; grade 3 hypertension that was readily managed will be permittedXx_NEWLINE_xXAny ongoing toxicity ? Grade 2 attributable to prior Non-Small-Cell Lung Cancer (NSCLC) treatmentXx_NEWLINE_xXToxicity from prior therapy (excluding alopecia) that has not resolved to =< grade 1 prior to the first treatment with G-202Xx_NEWLINE_xXBaseline toxicities from prior anti-cancer treatments > grade 1Xx_NEWLINE_xXknown and persistent (>4 weeks) >/= grade 3 toxicity or fatigue from prior cancer treatment.Xx_NEWLINE_xXPatients must not have >= grade 2 diarrheaXx_NEWLINE_xXRecovery to Grade 1 or baseline of any toxicity due to prior systemic treatments (excluding alopecia).Xx_NEWLINE_xXSubjects must have recovered from toxicities of prior therapies. (i.e. CTCAE ? grade 2).Xx_NEWLINE_xXExisting severe major organ dysfunction i.e., renal, cardiac, hepatic, neurologic, pulmonary, or gastrointestinal toxicity >= grade 3 except for hearing loss, alopecia, anorexia, nausea, hyperbilirubinemia and hypomagnesemia from total parenteral nutrition (TPN), which may be grade 3Xx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopeciaXx_NEWLINE_xXPersistent clinically significant toxicities (Grade ?2) from previous anticancer therapy (excluding Grade 2 chemotherapy-related neuropathy and alopecia which are permitted). Prior toxicities that resulted in laboratory abnormalities should have resolved to Grade ?1. If medical therapy is required for the treatment of a laboratory abnormality, the dose and laboratory value(s) should be stable.Xx_NEWLINE_xXA history of any grade immune-related ocular event.Xx_NEWLINE_xXA history of Grade ?3 immune-related adverse event regardless of offending agent.Xx_NEWLINE_xXPreviously received an immune therapy that was discontinued due to immune-related AEs, regardless of grade.Xx_NEWLINE_xXPresence of ? CTCAE grade 2 toxicity (except alopecia, peripheral neuropathy and ototoxicity, which are excluded if ? CTCAE grade 3) due to prior therapy.Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or has not recovered (i.e. =< grade 1 or at baseline) from AEs due to a previously administered agent\r\n* Note: Patients with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If patient received major surgery, she must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAll grade >= 2 toxicities other than alopecia from prior therapy have resolved by the time of study commencementXx_NEWLINE_xXMust have recovered from all treatment-related toxicities to Grade 1 or less.Xx_NEWLINE_xXToxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversible. Certain non-serious exceptions include alopecia, hypothyroidism, neuropathy, nausea, adrenocortical deficiency requiring physiologic replacement dose of steroids, and other conditions noted and approved by the principal investigator (PI).Xx_NEWLINE_xXToxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversible. Certain non-serious exceptions include alopecia, hypothyroidism, neuropathy, nausea, adrenocortical deficiency requiring physiologic replacement dose of steroids, and other conditions noted and approved by the PI.Xx_NEWLINE_xXPrior chemotherapy must have been completed 21 days prior to initiation of protocol therapy and all toxicities must < grade 2.Xx_NEWLINE_xXIntolerance to bevacizumab defined as any NCI CTCAE grade 3 or grade 4 toxicity attributed to this agent that required discontinuation of bevacizumab (e.g., arterial thromboembolism [ATE], perforation, wound healing difficulty, proteinuria, reversible posterior leukoencephalopathy syndrome [RPLS]); Note: patients with prior grade 3 bevacizumab-related hypertension may be permitted if hypertension was manageable with standard oral antihypertensives as so judged by the treating physicianXx_NEWLINE_xXAny reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =< 1 except neuropathyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If participant underwent major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy\r\n* Note: Participants with alopecia are an exception to this criterionXx_NEWLINE_xXPersisting toxicity related to prior therapy of grade > 1 NCI-CTCAE v 4.03; however, alopecia, sensory neuropathy grade =< 2 or other grade =< 2 adverse events (AEs) not constituting a safety risk based on investigator's judgment are acceptableXx_NEWLINE_xXPatients are not eligible if they have an intolerance to most recent prior TKI (other than dasatinib) at the lowest possible effective dose, defined as a grade >= 3 toxicity considered at least possibly related to that TKI; patients are also excluded if they are intolerant or allergic to dasatinib and discontinued prior therapy due to a >= grade 2 treatment related adverse eventXx_NEWLINE_xXPatients should have discontinued any and all other therapy for CLL >= 48 hours prior to start of study therapy and recovered from any toxicity due to these therapies to grade =< 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to receipt of study medication or who has not recovered (i.e., =< grade 1 or at baseline; excludes alopecia and grade 2 neuropathy) from adverse events due to a previously administered agent\r\n* If subject had major surgery, they must have recovered adequately from the toxicity and complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade1Xx_NEWLINE_xXHave discontinued previous therapies for cancer (including specifically, aromatase inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia or peripheral neuropathy.Xx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., >= grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovery from acute toxicity related to prior therapy, including surgery and radiation, or no toxicity >= grade 2Xx_NEWLINE_xXToxicities from prior therapies that have not resolved to grade 1 or grade 0Xx_NEWLINE_xXAny unresolved toxicity NCI CTCAE Grade ?2 from previous anticancer therapyXx_NEWLINE_xXA minimum of two weeks since last dose of most recent RCC therapy assuming resolution of clinically significant treatment-related toxicities to grade 1, baseline, or controlled with supportive medicationsXx_NEWLINE_xXRecovered from all toxicities associated with prior treatment, to acceptable baseline status or grade 1 or less, except for toxicities not considered a safety risk, such as alopecia or vitiligo; peripheral neuropathy must be grade 2 or lessXx_NEWLINE_xXSubject has adequately recovered from toxicities due to prior HCC therapy to ? gradeXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients with acute GVHD grade II-IVXx_NEWLINE_xXPrior mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered (i.e., ? Grade 1 or at baseline) from AEs due to a previously administered agent.Xx_NEWLINE_xXPatients must be at least 2 weeks from prior chemotherapy, including biologics or targeted therapy (i.e. everolimus), or radiotherapy, or any investigational drug product, with adequate recovery of toxicity to baseline, or grade < 1, with the exception of alopecia and hot flashes; there is no washout period for prior endocrine therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 3 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXGrade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXAll adverse events related to prior therapies (chemotherapy, radiotherapy, and/or surgery) must be resolved to =< grade 1, except for alopeciaXx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1Xx_NEWLINE_xXELIGIBILITY FOR TREATMENT ON ARM 1: Patients treated with prior immunotherapy including and not limited to vaccines, cytokines, T cell stimulating agents, cytotoxic T lymphocyte antigen 4 (CTLA4) inhibitors and programmed death (PD)-1 check point inhibitors are allowed on therapy provided they did not have any severe grade 4 toxicities due to prior therapy and any toxicities due to prior therapy should have resolved, if resolvable to less than or equal to grade 1Xx_NEWLINE_xXSide effects from prior treatment have not resolved to =< grade 1 (or baseline due to previously administered agent/pre-existing conditions)Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXDehydration CTCAE (version 4.0) grade >= 1Xx_NEWLINE_xXUnresolved toxicity greater than CTCAE (version 4.0) grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin induced neurotoxicity =< grade 2Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny prior Grade ?3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1Xx_NEWLINE_xXReceived prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study registration or who has not recovered (i.e., ? Grade 1 or at baseline) from adverse events from previously administered agents. NOTE: Subjects with ? Grade 2 neuropathy are an exception to this criterion and can still be considered for the study.Xx_NEWLINE_xXRecovered from toxicities of prior therapy to grade 0 or 1Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with alopecia, =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXExpansion Cohort only: Patients with high grade glioma (grade 3 and 4) that are refractory to standard therapies, and who have progressive disease following radiation therapy. Patients with any number of prior treatments are allowed.Xx_NEWLINE_xXSubjects who have not recovered to Grade 0 or 1 toxicity from previous anti-cancer treatments or previous investigational agents.Xx_NEWLINE_xXSubjects with primary CNS malignancy other than high grade glioma (Grade 3 or 4)Xx_NEWLINE_xXAny unresolved toxicity NCI CTCAE Grade ?2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterion;Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXParticipants must have recovered to grade 1 toxicity from prior therapyXx_NEWLINE_xXPatient has >= CTCAE grade 2 diarrheaXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the studyXx_NEWLINE_xXFailure to recover to grade 1 or baseline from all toxic effects of previous chemotherapy, radiation therapy, biologic therapy, and/or experimental therapy, with the exception of: alopecia, grade =< 2 peripheral neuropathy, grade =< 2 cetuximab-related rash or other skin changes, hypomagnesemia (acceptable values detailed below), hypokalemia (acceptable values detailed below), and the acceptable hematologic values summarized above; a washout period of 2 weeks from prior cetuximab is required; a washout period of 3 weeks from any prior cytotoxic chemotherapy or investigational drug is requiredXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXToxicity from prior radiation therapy has NOT resolved to grade 1 or lessXx_NEWLINE_xXRecovered from prior radiotherapy and/or systemic therapy related toxicities to grade =< 1Xx_NEWLINE_xXPatients with history of proteinuria grade >= 2Xx_NEWLINE_xXAll AEs while receiving prior immunotherapy must have resolved to ? Grade 1 or baseline prior to screening for this study.Xx_NEWLINE_xXMust not have experienced a ? Grade 3 AE or neurologic or ocular AE of any grade while receiving prior immunotherapyXx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXAny unresolved toxicity NCI CTCAE Grade ?2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criterionXx_NEWLINE_xXGrade ? 2 toxicity (other than alopecia).Xx_NEWLINE_xXAny unresolved toxicity CTCAE >Grade 2 from the prior chemoradiation therapy.Xx_NEWLINE_xXHave discontinued previous therapies for cancer (including specifically, aromatase inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia or peripheral neuropathyXx_NEWLINE_xXToxicities related to prior therapy must either have returned to =< grade 1, baseline, or deemed irreversibleXx_NEWLINE_xXSubjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or ? Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both, including residual neuropathy.Xx_NEWLINE_xX? CTCAE Grade 3 anemia, ORXx_NEWLINE_xX? CTCAE Grade 3 hematoma (bleed)Xx_NEWLINE_xXUnresolved toxicity higher attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin- induced neurotoxicity ? Grade 2 for at least 14 days;Xx_NEWLINE_xXPatients must have recovered from the toxicity of prior therapy to less than grade 2Xx_NEWLINE_xXToxicities related to prior therapy must either have returned to =< grade 1, baseline or deemed irreversibleXx_NEWLINE_xXAny unresolved toxicity CTCAE >Grade 2 from previous anti-cancer therapy.Xx_NEWLINE_xXAny prior Grade ?3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1Xx_NEWLINE_xXPatients with > grade 1 neurologic toxicity at the time of treatmentXx_NEWLINE_xXSubjects with a history of Grade 4 astrocytoma.Xx_NEWLINE_xXPatients may have been treated with locoregional therapies such as major surgery, radiation, radiofrequency ablation, or cryosurgery provided this has been completed at least 4 weeks prior to registration and recovered from therapy related toxicity to less than CTCAE grade 2Xx_NEWLINE_xXPatients will be ineligible if they have a baseline neurologic toxicity of grade 3 or greaterXx_NEWLINE_xXRecovery to =< grade 1 toxicities associated with prior therapyXx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXAny Grade 3 or 4 toxicities (according to NCI CTCAE) resolved for at least 2 weeks prior to first treatmentXx_NEWLINE_xXRecovery from effects of recent treatment to baseline or CTCAE =< grade 1 toxicity from all prior therapies except alopecia and other non-clinically significant adverse events (AEs), unless the principal investigator (PI) determination is that the electrolyte imbalance is a result of the disease processXx_NEWLINE_xXAll adverse events (excluding alopecia, acne, rash) due to agents administered more than 2 weeks earlier should recover to =< grade 1; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (adverse events [AE]) and do not need to resolve to =< grade 1Xx_NEWLINE_xXGrade ? 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation.Xx_NEWLINE_xXPatients must have recovered to =< grade 1 in terms of toxicity from prior treatments (excluding neuropathy which can be =< grade 2)Xx_NEWLINE_xXReceived any anti-cancer or investigational therapy within 28 days prior to the first dose of study drug or has not recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(ies) of any previous therapyXx_NEWLINE_xXAll toxicity related to prior cancer therapies must have resolved to ? Grade 1, with the following exceptions: alopecia; neuropathy, which must have to resolved to ? Grade 2; and congestive heart failure (CHF), which must have been ? Grade 1 in severity and must have resolved completely.Xx_NEWLINE_xXAny prior Grade ? 3 immune-related adverse event (irAE) or any prior corticosteroid-refractory irAE.Xx_NEWLINE_xXWith the exception of alopecia or toxicities related to the use of gonadotropinreleasing hormone agonists, any unresolved toxicities from prior therapy greater than CTCAE Grade 2 at the time of starting study treatment.Xx_NEWLINE_xXInadequate recovery from any toxicity related to prior treatment (to grade 2 or baseline)Xx_NEWLINE_xXHistologically confirmed GBM (grade 4 astrocytoma) NOTE: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) may be included, primitive neuroectodermal tumor (PNET) variants are excluded; grade 4 oligodendrogliomas or oligoastrocytomas are specifically excludedXx_NEWLINE_xXAny ongoing toxicity related to prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (exceptions include alopecia, fatigue, and hematologic toxicities)Xx_NEWLINE_xXHistory of immune-mediated adverse events requiring immunosuppressive therapy or were grade 3 or higher related to prior immune-modulatory therapyXx_NEWLINE_xXHistory of ? Grade 2 pancreatitisXx_NEWLINE_xXAny systemic therapy associated toxicity should be grade 1 or lessXx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade ? 1 except for alopeciaXx_NEWLINE_xXHistory of any of the following during first-line therapy with a bevacizumab-containing regimen: arterial thrombotic/thromboembolic event, bowel perforation, Grade 4 hypertension, Grade 3 proteinuria or Grade 3 - 4 bleeding event.Xx_NEWLINE_xXPersisting toxicity related to prior therapy >Grade 1Xx_NEWLINE_xXGrade 2 or greater toxicities from prior therapy, except for Grade 2 toxicities that are not expected to resolve and that in the judgment of the Investigator do not pose a significant safety risk to subject participation.Xx_NEWLINE_xXPART B: Previous treatment related side-effects/adverse events must have resolved to at least grade 1 or, at the discretion of the investigator, select stable grade 2 toxicities (e.g. alopecia or fatigue) may be permissible if unchanging in grade for at least 3 months following discussion with the principal investigator (PI)Xx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXSubjects must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy, or other therapy intended for the treatment of cancer. (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor.)Xx_NEWLINE_xXSubjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or? Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both.Xx_NEWLINE_xXPatients must have recovered from acute toxicity (to grade 1 or less) of all previous therapy prior to enrollment. Treatment may start earlier if necessitated by the patient's medical condition (e.g. progressive disease) following discussion with the Investigator.Xx_NEWLINE_xXRecovery from acute toxicity related to prior therapy, including surgery and radiation, or no toxicity >= grade 2Xx_NEWLINE_xXPatients with diarrhea CTCAE v4 grade >= 2Xx_NEWLINE_xXUnresolved toxicity higher than CTCAE v. 4.0 grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be =< grade 2)Xx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baselineXx_NEWLINE_xXRecovered from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)Xx_NEWLINE_xXAny ongoing toxicity from prior hormonal therapy that is > grade 1 and/or that is progressing in severityXx_NEWLINE_xXPatients who have had systemic chemotherapies or targeted therapies within 3 weeks or radiotherapy within 2 weeks prior to entering the study or those patients whose adverse events from prior therapies have not recovered to =< grade 1 (other than grade 2 neuropathy, lymphopenia and alopecia which are permitted)Xx_NEWLINE_xXPatients with diarrhea >= CTCAE v4 grade 2Xx_NEWLINE_xXPatients who have received radiation therapy =< 2 weeks prior to study entry; patients who have received prior radiotherapy must have recovered from toxicity (=< grade 1) induced by this treatmentXx_NEWLINE_xXPrior hormonal/endocrine therapy =< 2 weeks prior to study entry (except for letrozole, which does not need to be interrupted); patients must have recovered from toxicity > grade 1, except for alopeciaXx_NEWLINE_xXPrior HER2-targeted therapy < 3 weeks prior to study entry; patients must have recovered from toxicity > grade 1, except for alopeciaXx_NEWLINE_xXUnresolved diarrhea >= CTCAE (v4.0) grade 1Xx_NEWLINE_xXResidual toxicity resulting from previous therapy (for example, hematologic, cardiovascular, or neurologic toxicity that is Grade >/=2). Alopecia is permittedXx_NEWLINE_xXRecurrent high grade gliomaXx_NEWLINE_xXGrade > 2 treatment-related toxicity from prior therapyXx_NEWLINE_xXUrinalysis with < grade 1 proteinuriaXx_NEWLINE_xXCompleted > 80% of the prescribed radiation therapy and concurrent temozolomide according to the Stupp regimen without grade 3 or 4 hematologic toxicityXx_NEWLINE_xXPatient must not be experiencing any ongoing toxicity from prior anti-cancer therapy that is > grade 1 or that is progressing in severity, except alopeciaXx_NEWLINE_xXPatients must have received prior rituximab therapy and must have recovered from all non-hematologic toxicities; (previous radiation is allowed as long as patients have recovered from all treatment related toxicities)Xx_NEWLINE_xXPatients must be at least 4 weeks from any prior treatments and have recovered (to < grade 2) from acute toxicity attributed to this prior treatmentXx_NEWLINE_xXRecovered from all reversible toxicities related to their previous treatment (other than alopecia) to =< grade 1 or baselineXx_NEWLINE_xXAny prior Grade ? 3 irAE while receiving immunotherapyXx_NEWLINE_xXToxicities related to prior therapy must either have returned to =< grade 1 or baseline or been deemed irreversible and in the opinion of the investigator not worsenedXx_NEWLINE_xXPathological diagnosis for the recurrent disease demonstrate transformation to higher grade (i.e. WHO grade III or IV) gliomas, even if the initial diagnosis was WHO grade II gliomaXx_NEWLINE_xXRecovery from non-hematological toxicities of prior therapy (including HSCT) to no more than grade 1 (except alopecia)Xx_NEWLINE_xXDiagnosis of HGG or DIPG; if histologic confirmation was obtained, diagnosis must be one of the following: anaplastic astrocytoma (World Health Organization [WHO] grade 3), anaplastic oligodendroglioma (WHO grade 3), anaplastic oligoastrocytoma (WHO grade 3), anaplastic ganglioglioma (WHO grade 3), pleomorphic xanthoastrocytoma with anaplastic features (WHO grade 3), malignant glioneuronal tumor, glioblastoma, or gliosarcoma (WHO grade 4)Xx_NEWLINE_xXRecovery to =< grade 1 from all significant toxicities of previous therapiesXx_NEWLINE_xXAny previous history of >= grade 3 toxicity to DasatinibXx_NEWLINE_xXSodium levels =< grade 1Xx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXPatients must have recovered to =< grade 1 toxicity (except alopecia and hearing loss) from any prior chemotherapy, other investigational therapy, hormonal, biological, targeted agentsXx_NEWLINE_xXAny history of previous >= grade 3 toxicity attributable to erlotinib (except dermatological toxicity)Xx_NEWLINE_xXAny grade 3 or 4 -hematologic toxicity of previous therapy must have resolved to grade 2 or less prior to apheresis and any grade 3 or 4 toxicity must have resolved to grade 2 or less prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXPatients must be at least 2 weeks from prior chemotherapy or radiotherapy, or any investigational drug product with adequate recovery of toxicity to baseline, or grade =< 1, with the exception of alopecia and hot flashes; there is no washout period for prior endocrine therapyXx_NEWLINE_xXChemotherapy administered for the diagnosis of seminoma:\r\n* Prior chemotherapy for a different cancer is allowed, provided therapy was completed more than twelve months from first fraction of proton therapy administered in this study and the participant has recovered to grade =< 1 toxicity related to agents previously administeredXx_NEWLINE_xXResolution of all chemotherapy or radiation-related toxicities to grade 1 severity or lower except for alopeciaXx_NEWLINE_xXPatients with GOG performance grade of 3 or 4Xx_NEWLINE_xXReceived treatment with chemotherapy, radiation, antibody therapy or other immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, or experimental drugs 14 days prior to first dose of rucaparib and/or ongoing adverse effects from such treatment > NCI CTCAE Grade 1 (Grade 2 non-hematologic toxicity to most recent treatment may be permitted with prior advanced approval from Sponsor).Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severityXx_NEWLINE_xXUnresolved toxicities from prior therapy with the exception of alopecia that have not resolved to ? Grade 1 at the time of starting study treatmentXx_NEWLINE_xXAny ongoing toxicity from prior investigational therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXLast anti-cancer treatment (including any investigational drug) >= 2 weeks from initiation of protocol-based therapy, and provided all adverse events (AEs) (other than alopecia) have resolved to =< grade 1 at baselineXx_NEWLINE_xXGrade >1 retinopathyXx_NEWLINE_xXRecovered from all reversible toxicities related to their previous treatment (other than alopecia) to =< grade 1 or baselineXx_NEWLINE_xXUnresolved toxicity higher than CTCAE v. 4.0 grade 1 attributed to any prior therapy/procedure excluding alopecia and oxaliplatin-induced neurotoxicity (which must be =< grade 2)Xx_NEWLINE_xXPersistent toxicities >= grade 2 from prior chemotherapy or biological therapy regardless of interval since last treatmentXx_NEWLINE_xXHas recovered from all therapy-related toxicity to =< grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy)Xx_NEWLINE_xXHad prior chemotherapy, targeted small molecule therapy within 4 weeks, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to a previously administered agent - Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study - Note: if a subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy -\r\n Note: patients who have received > 30 Gy to the thorax must have completed this radiation 6 months prior to enrollment in the studyXx_NEWLINE_xXPatient did not discontinue due to a Grade ?3 related adverse eventXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity; hypothyroidism treated with medication is not excluded if thyroid-stimulating hormone (TSH) is within normal limitsXx_NEWLINE_xXEXPANSION COHORT ONLY: Resolution of any pre-existing toxicity from prior therapy to NCI CTCAE version 4.0 =< grade 1 except neuropathy (=< grade 2) and tinnitus (=< grade 2), and hearing loss (=< grade 4)Xx_NEWLINE_xXEXPANSION COHORT ONLY: Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity; hypothyroidism treated with medication is not excluded if TSH is within normal limitsXx_NEWLINE_xXSubject has recovered from toxicities of prior chemotherapy or other therapy (to grade 2 or less)Xx_NEWLINE_xXAdequate recovery from any adverse events resulting from prior anti-neoplastic treatment including chemotherapy, biological therapy, targeted small molecule therapy, radiation therapy, and surgery as determined by the investigator (and in consultation with the study PI); in most instances, adequate recovery is resolution to =< grade 1 except for alopecia of any grade, grade 2 neuropathy and/ or any grade hearing lossXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXRecovery to baseline or ? Grade 1 CTCAE v4 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy.Xx_NEWLINE_xXAny unresolved toxicity (> CTCAE grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., alopecia, hearing loss, peripheral neuropathy)Xx_NEWLINE_xXGrade 3 histologyXx_NEWLINE_xXParticipants who have had endocrine, chemotherapy, and/or biologic therapy < 14 days prior to entering the study or those who have not recovered from any prior treatment-related toxicities (must recover to no more than grade 1; alopecia, sensory neuropathy grade =< 2, or other grade =< 2 toxicity not constituting a safety risk based on investigator’s judgment are acceptable)Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXAdverse events (AEs) from prior anticancer therapy that have not resolved to grade =< 1 except for alopeciaXx_NEWLINE_xXAny toxicity related to prior cancer therapies that has not resolved to =< grade 1, with the exception of peripheral neuropathy, which must have resolved to =< grade 2, and alopeciaXx_NEWLINE_xXHave not recovered (to baseline or Grade ?1) from toxicity associated with prior treatment.Xx_NEWLINE_xXCTCAE version 4.03 > grade 2 pulmonary hemorrhage or > grade 3 of other forms of bleeding within 28 days prior to enrollment.Xx_NEWLINE_xXAny unrecovered toxicity reactions of CTCAE version 4.03 > grade 1 caused by any previous therapy (excluding alopecia and neurotoxicity < grade 2)Xx_NEWLINE_xXResolution of (non-laboratory) adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =< 1 prior to first study treatment (with the exception of alopecia or neuropathy)Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXFemale subjects with histologically diagnosed relapsed high-grade serous or high-grade endometrioid ovarian cancer;Xx_NEWLINE_xXHave resolution of all previous treatment-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy (less than or equal to Grade 2) or alopecia. If subject received major surgery or radiation therapy of > 30 Gy, must have recovered from the toxicity and/or complications from the intervention.Xx_NEWLINE_xXHad a prior anti-cancer monoclonal antibody (except immune CPI in the case of melanoma subjects) within 30 days prior to start of study treatment, or failure to recover to CTCAE Grade 1 or better from the adverse events of prior therapiesXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n*Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXToxicity from prior chemotherapy that has not resolved to Grade ? 1;Xx_NEWLINE_xXGrade 3/4 proteinuriaXx_NEWLINE_xXResolution of all chemotherapy related grade III-IV toxicity as per Common Toxicity Criteria (CTC) criteria 4.0Xx_NEWLINE_xXResolution of all chemotherapy related grade III-IV toxicity as per CTC criteria 4.0Xx_NEWLINE_xXPatients must not have a history of grade >= 2 neurological toxicity with previous treatment, or persistent grade >= 2 peripheral neuropathy; drowsiness and lethargy were exempted from this criteria unless previously persistent for more than one weekXx_NEWLINE_xXAny prior therapies such as surgery, chemoembolization, radiofrequency ablation, and alcohol injection are allowed as long as toxicity from such prior therapy is =< grade 1Xx_NEWLINE_xXPRIOR TO MOBILIZATION THERAPY: Resolution of grade III-IV toxicity associated with pre-transplant therapyXx_NEWLINE_xXPRIOR TO HIGH-DOSE CHEMOTHERAPY: Patients without evidence of ongoing grade III-IV toxicity related to mobilization therapyXx_NEWLINE_xXRecovered from all clinically relevant toxicities related to prior therapiesXx_NEWLINE_xXGrade >1 retinopathyXx_NEWLINE_xXPathological diagnosis of astrocytoma grade 2, oligodendroglioma grade 2, or oligoastrocytoma grade 2 (mixed glioma containing astrocytoma and oligodendroglioma); pilocytic astrocytoma, ganglioglioma, pleomorphic xanthoastrocytoma, or dysembryoplastic neuroepithelial tumors are not eligible\r\n* NOTE: if the pathology from multiple procedures supports the diagnosis of a brain tumor, the qualifying pathology of grade 2 astrocytoma, oligodendroglioma, or oligoastrocytoma must be the most recent pathological diagnosis, and a pathological diagnosis of a grade 3 or grade 4 glioma must not have been made at any timeXx_NEWLINE_xXMore than three weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)Xx_NEWLINE_xXIf patient has received previous systemic treatment, at least 4 weeks must have elapsed since the last chemotherapy, radiotherapy or immunotherapy and the beginning of protocol therapy and the patient must have recovered from toxicity due to the previous therapy (i.e., toxicity has resolved to baseline or is deemed irreversible)Xx_NEWLINE_xXNewly diagnosed tumor of the CNS, to include patients with:\r\n* Medulloblastoma (all histologic subtypes)\r\n* Supratentorial primitive neuro-ectodermal tumors (PNET) (including CNS neuroblastoma or ganglioneuroblastoma, medulloepithelioma, and ependymoblastoma)\r\n* Pineoblastoma\r\n* Atypical teratoid rhabdoid tumor (ATRT)\r\n* Choroid plexus carcinoma \r\n* High-grade glioma, including anaplastic astrocytoma (World Health Organization [WHO] grade III), anaplastic oligodendroglioma (WHO grade III), anaplastic oligoastrocytoma (WHO grade III), anaplastic ganglioglioma (WHO grade III), pleomorphic xanthoastrocytoma with anaplastic features (WHO grade III), high-grade astroblastoma, anaplastic pilocytic astrocytoma (WHO grade III), malignant glioneuronal tumor, glioblastoma multiforme (WHO grade IV) or gliosarcoma (WHO grade IV)\r\n* Patients with ependymoma (including all ependymoma histological variants)Xx_NEWLINE_xXHistologic diagnosis of high-grade glioma, including anaplastic astrocytoma (WHO grade III), anaplastic oligodendroglioma (WHO grade III), anaplastic oligoastrocytoma (WHO grade III), anaplastic ganglioglioma (WHO grade III), pleomorphic xanthoastrocytoma with anaplastic features (WHO grade III), high grade astroblastoma (WHO grade III), anaplastic pilocytic astrocytoma (WHO grade III), malignant glioneuronal tumor, glioblastoma multiforme (WHO grade IV) or gliosarcoma (WHO grade IV)Xx_NEWLINE_xXAll previous cytotoxic chemotherapy must be completed at least 2 weeks prior to study entry, with the exception of the tyrosine kinase inhibitors imatinib, nilotinib and dasatinib which may be continued through induction therapy; any grade 3 or 4 nonhematologic toxicity of any previous therapy must have resolved to grade 2 or less, unless specified elsewhereXx_NEWLINE_xXResolved acute effects of any prior therapy to baseline severity or Grade ?1 NCI CTCAE.Xx_NEWLINE_xXAll associated toxicity from previous or concurrent cancer therapy must be resolved (to ?Grade 1 or Baseline) prior to study treatment administrationXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* NOTE: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXFailure to recover to Grade 0 or Grade 1 from acute non-hematologic toxicity due to previous therapy, prior to screening (with the exception of alopecia).Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and/or alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXClinically significant toxic effects of any prior antitumor therapy (except hydroxyurea) resolved to Grade ? 1 before the start of study therapy (bone marrow parameters [Grade 1 to 4 permitted]);Xx_NEWLINE_xXRecovery to Grade 1 from all clinically significant adverse events related to prior MF therapy, including transplant-related toxicities.Xx_NEWLINE_xXAny unresolved toxicity (> CTCAE grade 2) from previous anti-cancer therapyXx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXSubject has an ongoing toxicity ? Grade 2 (NCI CTCAE Version 4.03) attributable to prior medication to treat solid tumor (except alopecia) at screening.Xx_NEWLINE_xXNo history of severe immune-related adverse effects from anti CTLA 4 (CTCAE Grade 3 and 4)Xx_NEWLINE_xXGrade > 2 treatment-related toxicity from prior therapyXx_NEWLINE_xXAll associated toxicity from previous or concurrent cancer therapy must be resolved (to ? Grade 1 or Baseline) prior to study treatment administration.Xx_NEWLINE_xXHistory of Grade ?3 infusion-associated adverse events (AEs) or hypersensitivities to NEOD001 or any of its excipientsXx_NEWLINE_xXRecovered from toxicities of previous anticancer therapy to CTCAE Grade ? 1 with the exception of alopecia.Xx_NEWLINE_xXResidual AEs >Grade 2 from previous treatmentXx_NEWLINE_xXToxicity recovery should include the following:\r\n* Grade =< 2 neuropathy\r\n* Grade =< 2 diarrhea\r\n* Grade =< 2 mucositisXx_NEWLINE_xXResidual AE from previous treatment > Grade 1Xx_NEWLINE_xXSubjects experiencing unresolved toxicity of previous antitumor therapy (excluding alopecia) which is CTCAE Grade >1 at screeningXx_NEWLINE_xXKnown grade 3 or 4 neurotoxicityXx_NEWLINE_xXPersistence of toxicity from previous chemo and/or radiotherapy > grade 2Xx_NEWLINE_xXOngoing toxicities >= grade 2 from prior therapyXx_NEWLINE_xXDiscontinuation of prior anticancer therapy for ? 7 days prior to C1D1 and recovered to ? CTCAE grade 2 (or baseline) from any acute or chronic toxicity associated with prior therapy.Xx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXUnresolved or unstable, serious toxicity from prior cancer treatment (any toxicities greater than grade 2)Xx_NEWLINE_xXHistory of pancreatitis of any gradeXx_NEWLINE_xXParticipants with history of chronic diarrhea, grade >= 2 prior to study participation; persons with up to grade 1 diarrhea will be eligibleXx_NEWLINE_xXGrade > 2 treatment-related toxicity from prior therapyXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); patients must have progressing disease after prior treatment; note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteriaXx_NEWLINE_xXPatients who have toxicity from last prior therapy that has not recovered to at least Grade 1, with the exception of Grade 2 alopeciaXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXPatients are permitted to have been treated with previous systemic chemotherapy; a minimal time interval since last dose of cytotoxic chemotherapy must be equal to or greater than 21 days, and all acute toxicities should be resolved to less than grade 2, and hematologic counts should meet study criteria; with regards to toxicity, patients who have left sided chest wall recurrences should not have previously exceeded more than 450 mg/m^2 doxorubicin due to expected cumulative cardiotoxicity; prior taxane therapy is allowed, however, there should be no reported anaphylactic reactions of grade 3 or higherXx_NEWLINE_xXAnxiety ? CTCAE grade 3Xx_NEWLINE_xX9. All prior cytotoxic toxicities must have resolved to grade ? 1 prior to randomization.Xx_NEWLINE_xXRecovered to Grade 1 from reversible toxicities of prior therapyXx_NEWLINE_xXSubjects who have not recovered from the adverse effects of prior therapy at the time of enrollment to ? grade 1; excluding alopecia and grade 2 neuropathy.Xx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.Xx_NEWLINE_xXResolution of prior treatment associated toxicities to ? grade 1Xx_NEWLINE_xXPatients must have Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 as below:\r\n* Grade 0: Up and about, no restriction\r\n* Grade 1: Ambulatory, no strenuous activity\r\n* Grade 2: Ambulatory, capable of self-care appropriate for age; up and about > 50% of time, but unable to carry out any physical activities or attend school\r\n* Grade 3: Limited self-care only; up and about < 50% of time\r\n* Grade 4: Disabled, no self-care; bedridden or confined to chairXx_NEWLINE_xXSerum cholesterol >= Grade 2Xx_NEWLINE_xXHypertriglyceridemia >= Grade 2Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo)Xx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients must have recovered from the acute treatment-related toxicities (defined as =< grade 1) of radiotherapy prior to entering this studyXx_NEWLINE_xXAny grade 4 laboratory abnormalitiesXx_NEWLINE_xXWith the exception of alopecia, any unresolved toxicities from prior chemotherapy should be no greater than CTCAE v4 grade 1 at the time of starting study treatmentXx_NEWLINE_xXHas ongoing acute clinical adverse events NCI CTCAE Grade >1 resulting from prior cancer therapies (except alopecia, TKI-related hand-foot syndrome, or thyroid dysfunction).Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXSubjects with valvular heart disease CTCAE (version 4.0) grade 2Xx_NEWLINE_xXAt least 2 weeks since last cytotoxic chemotherapy, hormonal therapy, or radiotherapy; toxicities related to prior therapy must either have returned to grade 1, or baseline (excluding alopecia)Xx_NEWLINE_xXPersisting toxicity related to prior therapy (Grade >1 NCI CTCAE v4.0); however, alopecia, sensory neuropathy (Grade 2 or less), or other (Grade 2 or less) adverse events not constituting a safety risk based on the investigator's judgement are acceptable.Xx_NEWLINE_xXResolution of adverse effects of recent surgery, radiotherapy, or chemotherapy to grade =< 1 prior to first study treatment (with the exception of alopecia or neuropathy)Xx_NEWLINE_xXThere are no limits on prior lines of therapy; however, patients must have recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to entering the study (except alopecia)Xx_NEWLINE_xXAll associated toxicity from previous or concurrent cancer therapy must be resolved (to ? Grade 1 or Baseline) prior to study treatment administration.Xx_NEWLINE_xXOngoing infection of ? Grade 2 severity.Xx_NEWLINE_xXPatients should be without any persisting clinically significant > grade 2 hematological/non hematological toxicities from previous treatments that would preclude evaluation of toxic effects of study treatment; grade 1 residual toxicity will be acceptable; patients should be off previous treatment at least 2 weeks from prior therapies before treatment startXx_NEWLINE_xXExperienced resolution of toxic effect(s) of the most recent prior anti-cancer therapy to Grade ?1 (except alopecia or neuropathy)Xx_NEWLINE_xXAll acute treatment-related toxicity from prior therapy must have resolved to Grade ? 1 prior to study entryXx_NEWLINE_xX? CTCAE Grade 3 anxiety.Xx_NEWLINE_xXCurrent Grade greater than (>) 1 toxicity (except alopecia and anorexia) from prior therapy or Grade >1 neuropathy from any causeXx_NEWLINE_xXParticipant with ? Grade 2 (CTCAE v 4.0-JCOG) persistent symptoms and objective findings due to the toxicity attributable to prior treatment with antitumor effect (except alopecia).Xx_NEWLINE_xXResolution of non-hematologic toxic effect(s) of NAC to =< grade 1 or baseline (except alopecia)Xx_NEWLINE_xXHas not recovered from the adverse effects of previous anti-cancer treatments to pre-treatment baseline or Grade 1, except for alopecia, anemia (hemoglobin must meet the present study inclusion criterion), and peripheral neuropathy (which must have recovered to ? Grade 2).Xx_NEWLINE_xXTreatment related residual toxicity > grade 1Xx_NEWLINE_xXHigh grade (or grade 3) serous histology or known to have gBRCAmutXx_NEWLINE_xXRecovery to grade ? 1 or to baseline from any AE derived from previous treatment (excluding alopecia of any grade).Xx_NEWLINE_xXPatient with an unresolved ? Grade 2 AE from a previous antineoplastic treatment, excluding alopecia.Xx_NEWLINE_xXPatient has an unresolved ? Grade 2 AE from a previous antineoplastic treatment, excluding alopecia.Xx_NEWLINE_xXResolution of all prior treatment-related toxicities to Grade 1 or less, except for Grade 2 fatigue or alopecia prior to C1D1Xx_NEWLINE_xXPersistent grade 2 fatigue at Baseline.Xx_NEWLINE_xXPatients with diarrhea > CTCAE grade 2.Xx_NEWLINE_xXRecovery to grade 1 or baseline of any toxicity due to prior anticancer therapies (excluding alopecia)Xx_NEWLINE_xXAcute prior study treatment related toxicity (except alopecia) that has not resolved to Grade < or = to 1 unless it has been deemed stable by the investigatorXx_NEWLINE_xXFailure to recover to Grade 1 or lower toxicity related to prior systemic therapy (excluding alopecia and neuropathy) prior to study entryXx_NEWLINE_xXPatients must have recovered (grade 1 or baseline) from any clinically significant toxicity associated with prior therapyXx_NEWLINE_xXFor Part A only: Participants who did not recover from all clinically significant toxicities (excluding alopecia and hematologic toxicities) of any previous surgery, radiotherapy, targeted therapy, or chemotherapy to less than or equal to Grade 1Xx_NEWLINE_xXOngoing toxic manifestations of previous treatments. Exceptions to this are alopecia or Grade 1 toxicities which, in the opinion of the Investigator, should not exclude the patient.Xx_NEWLINE_xXRecovered (i.e., Grade ? 1 or to a baseline level) from the effects of recent surgery, radiotherapy, chemotherapy, hormonal therapy, or other therapies for cancer (with the exception of alopecia for which no resolution is required and peripheral neuropathy which must have resolved to Grade ? 1 for subjects receiving prior taxane-based chemotherapy);Xx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baselineXx_NEWLINE_xXPatients must have recovered from acute side effects of HSCT, defined as having < grade 2 non-hematological toxicity related to the transplant (exceptions are alopecia and other non-acute toxicities)Xx_NEWLINE_xXLack of recovery from all toxicity from previous therapy to grade 1 or baselineXx_NEWLINE_xXDiarrhoea CTCAE v4.03 Grade ? 2Xx_NEWLINE_xXMust have full recovery from any toxicities from prior therapy CTCAE Grade 1 or less with the exception of Grade 2 alopecia) prior to randomization.Xx_NEWLINE_xXFailure to recover to grade 1 or less all prior adverse events.Xx_NEWLINE_xXGrade 3 immune mediated adverse event that was considered related to previous immunotherapy and required immune suppressive therapy;Xx_NEWLINE_xXGrade 2 hepatic function related adverse event that persisted more than 1 week, was considered related to immunotherapy, or required treatment discontinuation or immunosuppressive therapyXx_NEWLINE_xXInadequate recovery from any toxicities related to prior treatment (to grade 1 or baseline)Xx_NEWLINE_xXHistory of bronchopulmonary hemorrhage NCI CTCAE >/= Grade 2 within 2 months prior to randomizationXx_NEWLINE_xXPatients with chronic grade 1 or 2 toxicity may be eligible at the discretion of the principal investigator if the condition has been stable, and not worsening, for at least 30 days; patients with ongoing alopecia of any grade will be eligibleXx_NEWLINE_xXUnresolved clinically significant toxicity greater than Grade 2 from previous anti-cancer therapyXx_NEWLINE_xXRecovery from prior therapy toxicity, defined as resolution of all treatment-related adverse events (AEs) to Grade ? 1 or pre-treatment baseline (except alopecia and lymphopenia).Xx_NEWLINE_xXHas unresolved toxicities from prior anti-cancer therapies, defined as toxicities (chemotherapy, hormonal treatment, radiation, and/or surgery) not yet resolved to NCI-CTCAE, v4, Grade <= 1 or baseline; other than alopecia, skin toxicity (Grade 1), according to NCI-CTCAE, v4. Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator and Sponsor (e.g., Grade 2 chemotherapy-induced peripheral neuropathy).Xx_NEWLINE_xXAll acute treatment-related toxicity from prior therapy must have resolved to Grade ? 1 prior to study entryXx_NEWLINE_xXAny prior Grade ? 3 immune-related adverse event while receiving immunotherapyXx_NEWLINE_xXPrior treatment toxicities must be ? Grade 1Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v4.03 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria with the exception of alopecia. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by MEDI0680 (AMP-514) may be included (eg, hearing loss) after consultation with the MedImmune medical monitorXx_NEWLINE_xXHave unresolved toxicity from previous treatment or previous investigational agents; excluding alopecia; clinical judgment by the investigator is allowed to determine if grade 1 fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient’s general condition or disease; the investigator and medical monitor will discuss the eligibility of patients with baseline toxicityXx_NEWLINE_xXToxicity (except alopecia and anorexia) from prior therapy or neuropathy of grades >Xx_NEWLINE_xXPatients with grade >= 3 non-hematologic toxicity from previous therapy that has not resolved to =< grade 1Xx_NEWLINE_xXUnresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE Grade 0 or 1, or to the levels dictated in the eligibility criteria with the exception of alopeciaXx_NEWLINE_xXResolution of all prior ONT-10 related toxicities to ? Grade 1in severityXx_NEWLINE_xXAll acute treatment-related toxicity from prior therapy must have resolved to Grade ? 1 prior to study entryXx_NEWLINE_xXAll acute treatmentrelated toxicity from prior therapy must have resolved to Grade ? 1 prior to study entryXx_NEWLINE_xXSubjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or ? Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and Investigator may be allowed upon agreement with both.Xx_NEWLINE_xXPatient has recovered (to Grade ?1) from all clinically significant toxicities related to prior antineoplastic therapies.Xx_NEWLINE_xXThe patient has a prior ALK-inhibitor-related toxicity or any other prior therapy-related acute toxicity that has not resolved prior to the first dose of study drug.Xx_NEWLINE_xXRecovered from toxicities of previous anticancer therapy to CTCAE Grade ? 1 with the exception of alopecia.Xx_NEWLINE_xXThe subject has not recovered from toxicity due to all prior therapies (i.e., return to pretherapy baseline or to grade 0 or 1)Xx_NEWLINE_xXDehydration NCI-CTCAEversion 4.0 Grade ? 1Xx_NEWLINE_xXUnresolved toxicity higher than NCI-CTCAE version 4.0 Grade 1 attributed to any prior therapy/procedure (excluding alopecia or anemia or grade 2 neuropathy that is not reversible due to oxaliplatin)Xx_NEWLINE_xXPrior clinically significant grade 3-4 non-hematological toxicity to high dose Ara-C or grade ? 2 of neurological toxicity.Xx_NEWLINE_xXRecovery to =< grade 1 toxicities associated with prior therapyXx_NEWLINE_xXPatients should have recovered to baseline or =< grade 1 for all-prior treatment related toxicitiesXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; if the patient has residual toxicity from prior treatment, toxicity must be =< grade 1 (or =< grade 2 for peripheral neuropathy and/or alopecia)Xx_NEWLINE_xXNCI CTCAE (version 4.03) Grade 3 or higher toxicities due to prior therapy that have not shown improvement and are considered to interfere with current study medicationXx_NEWLINE_xXResidual > Grade 2 toxicity from prior treatment must have resolved with the exception of those explicitly described elsewhere in entry criteriaXx_NEWLINE_xXResidual toxicity of > grade 1 from prior therapyXx_NEWLINE_xXPatients must not have received any other treatment for their disease, including hematopoietic growth factors, within three weeks of beginning the trial, and should have recovered from all toxicities of prior therapy (to grade 0 or 1)Xx_NEWLINE_xXParticipants not recovered from reversible toxicity of prior anticancer therapy (except toxicities which are not clinically significant such as alopecia, skin discoloration, or Grade 1 neuropathy)Xx_NEWLINE_xXCTCAE Grade 2 or 3 fatigue.Xx_NEWLINE_xXCurrent diarrhea >= CTCAE grade 2Xx_NEWLINE_xXSubjects who have had any anticancer treatment prior to entering the study and have not recovered to baseline (except alopecia) or ? Grade 1 AEs, or deemed irreversible from the effects of prior cancer therapy. AEs > Grade 1 that are not considered a safety risk by the Sponsor and investigator may be allowed upon agreement with both.Xx_NEWLINE_xXThyroid function abnormality ? Grade 2Xx_NEWLINE_xXAny unresolved >=Grade 2 (per CTCAE v 4.0) toxicity from previous anti-cancer therapy at the time of enrollment, except alopecia or Grade 2 anemia (if hemoglobin is >9.0 g/dL)Xx_NEWLINE_xXAny >=Grade 2 hypophosphatemia (per CTCAE v4.0) at the time of enrolmentXx_NEWLINE_xXDehydration > grade 1Xx_NEWLINE_xXResolution of all acute toxicity effects of prior therapy to NCI CTCAE (version 4.0) grade =< 1, with the exception of unresolved grade 2 neuropathy and grade 2 alopecia, which are allowedXx_NEWLINE_xXNo limit to prior therapies with last anti-cancer treatment >= 2 weeks from initiation of protocol-based therapy provided all toxicities (other than alopecia) have resolved to =< grade 1 or baselineXx_NEWLINE_xXSubjects with abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (NOTE: subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study).Xx_NEWLINE_xXMust not be experiencing a Grade 3 or 4 toxicity from previous anti-cancer treatmentXx_NEWLINE_xXPresence of an acute or chronic toxicity resulting from prior anti-cancer therapy, with the exception of alopecia, that has not resolved to Grade ? 1 within 7 days prior to start of CA-4948 unless approved by the Medical MonitorXx_NEWLINE_xXHas not recovered (ie, to ? Grade 1 or to baseline) from chemotherapy induced AEs. Note: Patient with ? Grade 1 neuropathy or ? Grade 2 alopecia is an exception to this criterion and may qualify for the study. Persistent > Grade 2 toxicity from prior cancer therapyXx_NEWLINE_xXHas not recovered (ie, to ? Grade 1 or to baseline) from chemotherapy induced AEs. Note: Patient with ? Grade 1 neuropathy or ? Grade 2 alopecia is an exception to this criterion and may qualify for the study. Persistent > Grade 2 toxicity from prior cancer therapyXx_NEWLINE_xXAdverse events from prior anti-cancer therapy that have not resolved to Grade <=1 except for alopecia, vitiligo, or endocrinopathy managed with replacement therapyXx_NEWLINE_xXClinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade ? 1 (according to the NCI CTCAE, v4.0) prior to Cycle 1 Day 1Xx_NEWLINE_xXPatient has not recovered to baseline or less than Grade 1 from non-hematologic adverse events related to any anticancer therapy received prior to signing informed consent on the Treatment Extension study, with the exception of hair loss.Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specifiedXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time of treatment, and patients’ toxicities must have recovered to a grade 1 or less (except for alopecia or vitiligo); patients must have stable or progressing disease after prior treatment; note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteriaXx_NEWLINE_xXAll acute toxicities related to prior therapy must have resolved prior to study entry, except for alopecia and mild neuropathyXx_NEWLINE_xXGrade 2 or greater unresolved toxicity from prior antineoplastic therapyXx_NEWLINE_xXRecovered from all treatment-related toxicities to Grade 1 or less.Xx_NEWLINE_xXPatient who had not recovered to grade 1 or better from any adverse events (except alopecia, nausea, vomiting) related to previous antineoplastic therapy before screening procedures are initiated, as allowed in inclusion criteriaXx_NEWLINE_xX? CTCAE grade 3 anxietyXx_NEWLINE_xXAny subject with the following reported drug-related adverse events on anti- Cytotoxic T-Lymphocyte Antigen 4 (anti-CTLA4) will not be permitted on study: hepatic, diarrhea/colitis or endocrine adverse events (AE)s Grade ? 2, any other non-laboratory immune-related AE ? Grade 3. Subjects must have minimum 9 week washout period between the last dose of anti-CTLA4 and the first dose Urelumab (BMS-663513)Xx_NEWLINE_xXCurrent Grade >/= 2 toxicity (except for alopecia, anorexia and fatigue) from prior therapy or Grade >/= 2 neuropathyXx_NEWLINE_xXDiarrhea (> Grade 1)Xx_NEWLINE_xXAdequate recovery (to at least Grade 1) from toxicity of prior therapy as follows:Xx_NEWLINE_xXHas diarrhea (> Grade 1)Xx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia.Xx_NEWLINE_xXPatients must have recovered from any acute toxicity related to prior therapy, including surgery; toxicity should be =< grade 1 or returned to baselineXx_NEWLINE_xXPatients with diarrhea >= CTCAE grade 2Xx_NEWLINE_xXToxicities from previous cancer therapies must have recovered to CTCAE Grade = or < 2Xx_NEWLINE_xXAny unresolved toxicity greater than CTCAE grade 1 (except alopecia, and certain other unresolved CTCAE grade 2 toxicities including bone marrow hypocellularity, lymphopenia, infusion-related reaction, infusion site extravasation, injection site reaction, portal vein hypertension, obesity) from previous anti-cancer therapy; patients with grade 1 neuropathy will be evaluated on a case by case basis for entry into study; pre-chemotherapy medical conditions will be taken into considerationXx_NEWLINE_xXAll prior treatment related non-hematologic toxicities (with the exception of alopecia) must have resolved to CTCAE (Version 4.0) ? Grade 2 at the time of randomization.Xx_NEWLINE_xXPatients are eligible if standard or palliative measures do not exist or are no longer effective; at least 2 weeks should have elapsed since the last treatment and patients should have recovered from previous significant toxicity (i.e. to grade 1 or less); alopecia, skin discoloration, nail changes and other cosmetic changes are not considered significant toxicities; there is no limit on the number of prior therapies; patients may have received prior cisplatin or other platinum regimensXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severityXx_NEWLINE_xXPatients with unresolved grade > 2 non-hematologic toxicity from previous therapy; patients with grade 2 toxicity will be eligible at the discretion of the Principal Investigator (PI)Xx_NEWLINE_xXAll previous therapy must be completed at least 2 weeks prior to study entry; any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less, unless specified elsewhereXx_NEWLINE_xXAt least 3 weeks should have elapsed since the last cycle of cytotoxic therapy or since the last dose of radiation therapy, at least 4 weeks must have elapsed since the patient has received any investigational therapy or antibodies, and at least 7 days since the last dose of biologics (i.e. rapamycin or sorafenib), and patients should have recovered from toxic side effects of previous therapy to a grade 1 or less, with the exception of the following:\r\n* Hematological toxicity: recovered to levels required above\r\n* Low electrolyte levels (such individuals should receive appropriate supplementation)\r\n* For patients on anticoagulant therapy or with pre-existing coagulation abnormalities, PT and partial thromboplastin time (PTT) must return to baseline\r\n* Liver function tests must resolve to values required above\r\n* Grade 3 hypoalbuminemia\r\n* Alopecia\r\n* SterilityXx_NEWLINE_xXAt the time of enrollment, at least 3 weeks and no more than 8 weeks should have elapsed since the last cycle of cytotoxic therapy or since the last dose of radiation therapy, and patients should have recovered from toxic side effects of previous therapy to a grade 1 or less, with the exception of the following:\r\n* Hematological toxicity: recovery to required levels\r\n* Low electrolyte levels (such individuals should receive appropriate supplementation)\r\n* For patients on anticoagulant therapy or with pre-existing coagulation abnormalities, PT, PTT must return to baseline\r\n* Liver function tests must resolve to required values\r\n* Grade 3 hypoalbuminemia is permitted\r\n* Alopecia is permitted\r\n* Sterility is permittedXx_NEWLINE_xXPatients with pre-existing neurologic toxicity > grade 1 (as per CTCAE version 3.0) are not eligible for participation in cohort A; patients screened for participation in cohort B with pre-existing neurologic toxicity > grade 2 (as per CTCAE, version 3.0) are not eligible, unless pre-existing neurologic toxicity is documented in detail and patient's participation in the trial has been approved by the neuro-oncology team at participating institutionsXx_NEWLINE_xXAny on-going toxicity from prior anti cancer therapy except alopecia;Xx_NEWLINE_xXPatient experiencing unresolved toxicity ? CTCAE grade 2 (except alopecia) from previous agents.Xx_NEWLINE_xXAll previous therapy-related toxicities must have resolved or return to baseline.Xx_NEWLINE_xXPatients with diarrhea > CTCAE grade 1Xx_NEWLINE_xXAny unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy (except alopecia)Xx_NEWLINE_xXNo significant immune-related adverse event due to the nivolumab plus ipilimumab dose received in the neoadjuvant setting, as follows:\r\n* Any grade myocarditis, including an asymptomatic troponin elevation felt to be related to nivolumab plus ipilimumab\r\n* Any grade neurologic complication (e.g. meningitis, encephalitis, neuropathy); study chair should be contacted if there is any question whether an adverse event (AE) was neurologic in nature\r\n* Grade 2 or higher pneumonitis\r\n* Grade 2 colitis\r\n* Grade 2 or higher anemia (due to drug; unrelated anemia is not exclusionary)\r\n* Thyroid/adrenal AEs regardless of grade that have stabilized or are clinically asymptomatic are eligible\r\n* Fatigue, regardless of grade, is not a contraindication to randomization\r\n* Grade 4 AST or ALT elevation\r\n* Asymptomatic elevated amylase and lipase, regardless of grade, are not contraindications to randomization\r\n* Grade 4 rash; grade 3 rash is not a contraindication to randomization; any oropharyngeal lesions or bullous skin lesions that are suggestive of toxic epidermal necrolysis or Stevens-Johnson syndrome are contraindications to randomization regardless of the grade of rash\r\n** If not specified above, other Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher AEs deemed possibly related to the nivolumab plus ipilimumab are exclusions to randomization; AEs that were attributable to surgery or adjuvant RT would not be contraindications to randomizationXx_NEWLINE_xXSubject must have NCI common toxicity Grade 3-4 immune-related diarrhea for up to 3 days or persistent Grade 2 diarrhea for more than 5 daysXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; NOTE: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; NOTE: if subject received major surgery, s/he must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXAny unresolved toxicity (> CTCAE grade 2) from previous anti-cancer therapy; subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)Xx_NEWLINE_xXAny prior grade >= 3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE > grade 1Xx_NEWLINE_xXGrade >= 3 non-hematologic toxicity from prior therapy that has not resolved to =< G1Xx_NEWLINE_xXPatients must have recovered from non-hematologic toxicities associated with treatment of malignancy to less than or equal to grade 1Xx_NEWLINE_xXAll acute, clinically significant treatment-related toxicity from prior therapy, except for alopecia, must have resolved to grade =< 1Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); patients must have progressive disease after prior treatment\r\n* Note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patients’ toxicities must have recovered to a grade 1 or less (except for toxicities such as alopecia or vitiligo); Note: Patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXAny ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXOngoing infection > CTCAE grade 2Xx_NEWLINE_xXHas no Gleason grade 4 or 5,Xx_NEWLINE_xXPatient has received other chemotherapeutic, hormonal, or investigational anti cancer agents that are outside of the timeframe described above and thus would be allowed in the study, but has toxicity that is unresolved (i.e., toxicity has resolved to Grade ? 1 or is deemed irreversible)Xx_NEWLINE_xXHistologic diagnosis of glioblastoma (WHO grade IV) or pilocytic astrocytoma (WHO grade I)Xx_NEWLINE_xXReduction of any acute toxicity from radiation treatment to grade 1Xx_NEWLINE_xX>= grade 2 proteinuriaXx_NEWLINE_xXAny grade 3 or clinically significant grade 2 treatment-related non-hematological toxicity must be resolved to grade 1 before retreatment with chemotherapy (with exception of alopecia)Xx_NEWLINE_xXPatients with existing grade 2 toxicities, except as approved by the investigatorXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e. =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXHave unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment, including investigational treatment, with the exception of alopecia and ?Grade 1 peripheral neuropathy according to the NCI CTCAE v4.03. Clinical judgment by the investigator is allowed to determine if Grade 1 fatigue at screening is residual toxicity from prior treatment or is a symptom of the patient's general condition or disease. The investigator and Medical Monitor will discuss the eligibility of patients with baseline toxicity.Xx_NEWLINE_xXFailure to recover from all prior treatment-related non-hematological toxicities to ? Grade 1 prior to the first scheduled dose of MEDI7247 (except for alopecia and neuropathy).Xx_NEWLINE_xXHas had a prior monoclonal antibody within 4 weeks before study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from AEs due to agents administered more than 4 weeks earlier\r\n* Note: the following will not be exclusionary: patients may have any grade alopecia or lymphopenia and still participate if other inclusion/exclusion criteria are met; patients may have grade 1 or 2 neuropathy at baseline and still participate if other inclusion/exclusion criteria are metXx_NEWLINE_xXHave not recovered (recovery is defined as CTCAE grade ? 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.Xx_NEWLINE_xXHave not recovered (recovery is defined as CTCAE grade ? 1) from the acute toxicities of previous anticancer standard or investigational therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.Xx_NEWLINE_xXSubject that has toxicity from previous anti-cancer therapy must have recovered to ? Grade 1 (except for non-clinically significant toxicities, e.g., alopecia, vitiligo). Subjects with Grade 2 toxicities that are deemed stable or irreversible (e.g. peripheral neuropathy) can be enrolled.Xx_NEWLINE_xXPatients must not have had surgery, biologic therapy, or hormonal therapy within 14 days prior to registration; patients must not have had chemotherapy, targeted small molecule therapy, or radiation therapy within 28 days (42 days for nitrosoureas or mitomycin C) prior to registration; patients must not have had an investigational agent or monoclonal antibodies, except anti-PD1/L1 antibodies, within 28 days prior to registration\r\n* Patients must have recovered from all adverse events due to prior anti-cancer therapy (residual toxicity =< grade 1) prior to registration, with the exception of patients with =< grade 2 neuropath or =< grade 2 alopecia\r\n* If patients received major surgery, they must have recovered adequately from toxicity and/or complications from the intervention prior to registrationXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: Subjects with =< grade 2 neuropathy or typical side effects from radiotherapy are an exception to this criterion and may qualify for the study\r\n* NOTE: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients not recovered from any therapy-related toxicities from previous therapies to at least CTCAE ? Grade 1 except in case of liver metastases or Gilbert's Syndrome or alopecia.Xx_NEWLINE_xXNo grade 3 or 4 gastrointestinal (GI) toxicity at time of initial screeningXx_NEWLINE_xXSUBJECT: Must be off anti-neoplastic therapy for at least 2 weeks and all therapy-related toxicities should return to baseline or =< grade 1 if previously nonexistent.Xx_NEWLINE_xXRecovered from toxicity of any prior therapy to grade 1 or betterXx_NEWLINE_xXMajor bleed (WHO grade 3 or 4) within 6 months of enrollmentXx_NEWLINE_xXBaseline alopecia (defined CTCAE v4.0 grade > 0)Xx_NEWLINE_xXResolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade less than or equal to (</=) 1 prior to study entry, with the exception of alopeciaXx_NEWLINE_xXFailure to recover to Grade 1 or lower toxicity related to prior systemic therapy (excluding alopecia and neuropathy) prior to study entryXx_NEWLINE_xXGrade > 2 toxicity (other than alopecia) continuing from prior anti-cancer therapyXx_NEWLINE_xXPatients with prior immune checkpoint inhibitors must have related toxicities reduced to Grade 0, 1, or baselineXx_NEWLINE_xXNot recovered from toxicity due to all prior therapies.Xx_NEWLINE_xXUnresolved adverse events >= Grade 2 from prior anticancer therapy, except for alopecia.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; Note: subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study; Note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients must have had sufficient time between a prior therapy and resolution of toxicities from the prior therapies prior to registration as follows:\r\n* Prior EGFR inhibitor: A minimum of 7 days must have elapsed from the last dose of the prior EGFR inhibitor and resolution of any drug-related toxicity to =< grade 1 except for alopecia\r\n* Chemotherapy: A minimum of 21 days must have elapsed from the last dose and resolution of toxicity to =< grade 1 excluding =< grade 2 peripheral neuropathy or alopecia\r\n* Surgery: A minimum of 21 days must have elapsed following major surgery and resolution of toxicity to < grade 1 and complete wound healing must have occurred\r\n* Radiation: A minimum of 14 days must have elapsed following radiation therapy and resolution of all radiation induced toxicity excluding alopecia\r\n* Treatment with an investigational drug: A minimum of 3 months or five half-lives of the compound, whichever is greater, must have elapsed from last treatment dateXx_NEWLINE_xXAvailable for follow-up of their disease after treatment until progressive disease is documented and resolution of related adverse events until < grade 2Xx_NEWLINE_xXAny grade neurologic or ocular irAEXx_NEWLINE_xXAny grade immune-related pneumonitis, cardiomyopathy, or hepatitisXx_NEWLINE_xXFor Arms L (pembrolizumab) and M (nivolumab), history of a prior grade 3 or 4 immune-related adverse event (irAE) or any grade ocular irAE from prior immunotherapyXx_NEWLINE_xXParticipants must have recovered to grade 1 toxicity from prior therapyXx_NEWLINE_xX>= Grade 3 diarrhea, >= grade 3 rectal bleeding, abdominal cramping, or incontinence of stool =< 7 days prior to registrationXx_NEWLINE_xXPediatric patients who will receive cranial radiotherapy for brain tumors; this could include but is not limited to: low grade glioma, high grade glioma (to include grade III but not grade IV glioma), germ cell tumors, primitive neuroectodermal tumors, craniopharyngioma, or medulloblastomaXx_NEWLINE_xXPatients with GOG performance grade of 3 or 4Xx_NEWLINE_xXPatients with Acute GVHD Grade III-IVXx_NEWLINE_xXGleason grade 3+4 or lessXx_NEWLINE_xXPersistent clinically significant grade >= 2 toxicities (as per >= CTCAE v4) related to prior cancer therapyXx_NEWLINE_xXUnresolved toxicity from other agents; participants with unresolved or unstable Common Toxicity Criteria Adverse Event version 4 (CTCAE v4) grade 2 or greater toxicity from prior administration of another anti-cancer treatment are not eligibleXx_NEWLINE_xXAny grade 3 or 4 hematologic toxicity of any previous therapy must have resolved to grade 2 or less prior to apheresis and any grade 3 or 4 toxicity must have resolved to grade 2 or less prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXMust have received bilateral radiation therapy, and subsequently developed grade 2 or 3 xerostomia, according to modified Radiation Therapy Oncology Group (RTOG) scale:\r\n* Grade 0 – None\r\n* Grade 1 – Slight dryness of mouth (good response on stimulation and no significant dietary alterations necessary)\r\n* Grade 2 – Moderate dryness of mouth (poor response on stimulation and altered oral intake required such as frequent water, oral lubricants, or soft-moist foods)\r\n* Grade 3 – Complete dryness of mouth (no response on stimulation and difficult oral alimentation; intravenous (IV) fluids, pureed diet or tube feedings may be required)\r\n* Grade 4 – FibrosisXx_NEWLINE_xXAny unresolved toxicity from previous anti-cancer therapy must have resolved to at least =< grade 1 (or baseline) at time of enrollment\r\n* Patients with irreversible toxicity that is not reasonably expected to be exacerbated by treatment with durvalumab and tremelimumab may be included after consultation with the principal investigator or co-principal investigator (e.g. alopecia, hearing loss, peripheral neuropathy)Xx_NEWLINE_xXGrade 3 diseaseXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXPatients on adjuvant ipilimumab are allowed to participate at least 30 days from drug discontinuation as long as they have at most grade 1 adverse events (or grade 2 if they have to received hormone replacement therapy for their otherwise grade 1 ipilimumab-induced autoimmune endocrinopathies)Xx_NEWLINE_xXPrior radiation therapy for metastatic melanoma is allowed as long as the patient bears measurable actively growing disease outside the previously irradiated field\r\n* NOTE: if subject received major surgery, they must have recovered adequately from the toxicity (i.e., all symptoms =< grade 1) and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPHASE I: Cardiac, pulmonary, gastrointestinal and neurologic toxicity should all be =< grade 2Xx_NEWLINE_xXEXPANSION COHORT: Cardiac, pulmonary, gastrointestinal and neurologic toxicity should all be =< grade 2Xx_NEWLINE_xXMajor organ toxicity including cardiac, pulmonary, gastrointestinal and neurologic toxicity more than grade 2Xx_NEWLINE_xXPatient must not have any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity, except alopeciaXx_NEWLINE_xXNo tertiary Gleason grade >= 4Xx_NEWLINE_xXAll toxicities should recover to grade 0 or 1 prior to day 1Xx_NEWLINE_xXLOCALIZED RCC TREATED WITH PARTIAL NEPHRECTOMY:\r\nRecovered from toxicity of any prior therapy to >= grade 1Xx_NEWLINE_xXADVANCED RCC TREATED WITH RADICAL NEPHRECTOMY:\r\nRecovered from toxicity of any prior therapy to >= grade 1Xx_NEWLINE_xXHepatic toxicity >= grade 2 (using CTCAE version 4 standard definitions)Xx_NEWLINE_xXResidual toxicity due to previous anticancer therapy with no return to baseline or =< Grade 1 (except alopecia) according to CTCAE V4.03Xx_NEWLINE_xXToxicities due to prior therapy must be recovered to baseline or ? grade 1, except for clinically non-significant toxicities such as alopeciaXx_NEWLINE_xXDeveloped autoimmune disorders of Grade 4 while on prior immunotherapy. Subjects who developed autoimmune disorders of Grade ? 3 may enroll if the disorder has resolved to Grade ?1 and the subject has been off systemic steroids at doses >10 mg/day for at least 2 weeks.Xx_NEWLINE_xXResolution of all chemotherapy related grade III-IV toxicity as per Common Toxicity Criteria (CTC) criteria 4.0Xx_NEWLINE_xXResolution of all chemotherapy related grade III-IV toxicity as per CTC criteria 4.0Xx_NEWLINE_xXPatients with active diarrhea > CTCAE v4.03 grade 2Xx_NEWLINE_xXResolution of treatment-related toxicity to < grade 1; alopecia and cutaneous toxicity are allowed < grade 2Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 (except lenvatinib for patients in cohort 2) or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* NOTE: \r\n** Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n** If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to registration, as deemed by treating investigator or site PIXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must wait >= 3 weeks prior to starting study treatment, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXPatients entering into this study will have the presumptive diagnosis of high grade or low grade glioma based on imaging studies, or will have recurrent high-grade or low grade gliomas that have previously undergone diagnosis (astrocytoma, oligodendroglioma, mixed oligoastrocytoma, anaplastic astrocytoma, and glioblastoma multiforme); both of these groups will be undergoing craniotomy for tumor resectionXx_NEWLINE_xXPatients with low-grade (WHO grade I or II) gliomaXx_NEWLINE_xXongoing grade 2 or greater toxicities due to previous therapies. However, tolerable grade 2 adverse (e.g. neuropathy) events may be allowed at the discretion of the investigator.Xx_NEWLINE_xXSubjects with grade 2 or greater toxicities due to previous therapies (subject to the additional laboratory abnormalities listed below); however, tolerable grade 2 adverse (e.g. residual neuropathy from taxane or oxaliplatin) events may be allowed at the discretion of the investigatorXx_NEWLINE_xXUnresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ? 1 or baseline. Subjects with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor Medical Monitor or designee (eg, Grade 2 chemotherapy-induced neuropathy).Xx_NEWLINE_xXDiarrhea symptoms resolved to Grade 1 or better.Xx_NEWLINE_xXRecovery to grade ? 1 from any AE derived from previous treatment (excluding alopecia and/or cutaneous toxicity and/or asthenia).Xx_NEWLINE_xXNot recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE Grade <=1 or baseline.Xx_NEWLINE_xXThe patient has not recovered to grade ? 1 adverse events (AEs) due to investigational drugs or other medications, administered more than 2 weeks prior to the first dose of study drug, with the exception of neurotoxicity attributed to oxaliplatin or taxanes, which must have recovered to < 2 prior to study initiation.Xx_NEWLINE_xXCompleted a prior therapy less than (<) 2 weeks prior to first dose and for whom adverse events (AEs) related to prior therapy had not returned to baseline or improved to Grade 1.Xx_NEWLINE_xXgrade 3 to 4 nonhematologic toxicity that does not resolve with adequate interventionXx_NEWLINE_xXgrade 4 hematologic toxicity lasting more than 7 days, or a documented inability to sustain the TKI therapy because of recurrent grade 3 or 4 hematologic toxicity with re-initiation of the same therapyXx_NEWLINE_xXany grade 2 or greater toxicity that is unacceptable to the patientXx_NEWLINE_xXPatients who have received prior chemotherapy, other ALK inhibitors, biologic therapy, or other investigational agents, must have recovered from all toxicities related to prior anticancer therapies to grade ? 1 (CTCAE v 4.03) prior to starting study drug. Patients with grade ? 2 peripheral neuropathy or any grade of alopecia, nail changes or skin changes are allowed to enter the study.Xx_NEWLINE_xXFailure to recover from Grade 3 or 4 toxicity from previous treatmentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent\r\n* Note: subjects with =< grade 2 neuropathy and alopecia are an exception to this criterion and may qualify for the study\r\n* Note: if subject received major surgery, they must wait >= 3 weeks prior to starting study treatment; they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXFor Adjuvant Treatment: All AEs resulting from surgery must have resolved to NCI-CTCAE (v. 4.03) Grade ? 1Xx_NEWLINE_xXPrior systemic anticancer therapy within 4 weeks prior to enrollment or who has not recovered (i.e. ? Grade 1 or baseline grade) from adverse events due to a previously administered agentXx_NEWLINE_xXRecovery to Grade 1 of any clinically significant toxicity (excluding alopecia) prior to initiation of study drug.Xx_NEWLINE_xXHas not recovered (e.g., to ? Grade 1 or to baseline) from AEs due to a previously administered therapy.Xx_NEWLINE_xXUse of an investigational drug within 21 days prior to the first dose of study drug. Note that to be eligible, any drug-related toxicity should have recovered to Grade 1 or less, with the exception of alopecia.Xx_NEWLINE_xXUnresolved specific chronic toxicity of previous treatment of grade > 1 except for alopecia or hemoglobin ?9.0 g/dL (or ?5.6 mmol/L)Xx_NEWLINE_xXHave not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous investigational products (IPs)Xx_NEWLINE_xXRecovered from all reversible toxicities related to their previous treatment (other than alopecia) to =< grade 1 or baseline; exceptions to this criteria may be allowed at the discretion of the UNC PI for toxicities that are not expected to be exacerbated by pembrolizumab or nab-paclitaxelXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy including investigational agents within 4 weeks prior to study Day 1 or who has not recovered (i.e., ? Grade 1 or at baseline) from AEs due to a previously administered agent.Xx_NEWLINE_xXFailure to recover from acute non hematologic toxicity (except alopecia or Grade 2 or lower neuropathy), due to previous therapy, prior to Screening.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; patients who previously received RT in any form would not be eligible\r\n* Note: Subjects with =< grade 2 neuropathy are an exception to this criterion and may qualify for the study\r\n* Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXRecovery from prior surgery and recovery from adverse events to grade 1 or less (except alopecia) due to prior radiation therapy and any systemic therapy.Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1 or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to a previously administered agent; note: if subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy; note: toxicities that specifically define eligibility for this protocol (nephropathy, otopathy, neuropathy, or other as allowed by principal investigator [PI]) are exceptionsXx_NEWLINE_xX